Molecular Mechanisms of Chronic Pain and Therapeutic Interventions

Abstract

Chronic pain imposes incalculable health and economic burdens, affecting more than 30% of the global population in published studies. Optimal management of chronic pain is imperative for individuals experiencing such distress. Nevertheless, the current approaches to chronic pain assessment and treatment fail to meet clinical requirements. In recent years, there has been a growing recognition of the need for precision medicine approaches to effectively manage chronic pain. Chronic pain can be classified into three categories: nociceptive (resulting from tissue injury), neuropathic (caused by nerve injury), or nociplastic (arising from a sensitized nervous system). These classifications significantly impact the evaluation and treatment decisions at all levels. Significantly, in practice, there is substantial overlap in chronic pain mechanisms among patients and within different types of chronic pain. The application of precision medicine is imperative in the management of chronic pain. This review offers a comprehensive overview of the distinctive molecular mechanisms underlying nociceptive, neuropathic, and nociplastic pain, including immune responses, ion channels, monoaminergic imbalance, and neuroinflammation. Subsequently, we summarized the status quo of nociceptive, neuropathic, and nociplastic pain manipulation. Last, we explored the advances in pain management strategies for chronic pain that are making significant progress toward their clinical implementation.

Keywords

nociceptive pain / neuropathic pain / nociplastic pain / molecular mechanism / therapeutic interventions

References

[1] S. N. Raja, D. B. Carr, M. Cohen, et al., “The Revised International Association for the Study of Pain Definition of Pain: Concepts, Challenges, and Compromises,” Pain 161, no. 9 (2020): 1976-1982.

[2] B. Cao, Q. Xu, Y. Shi, et al., “Pathology of Pain and Its Implications for Therapeutic Interventions,” Signal Transduct Target Ther 9, no. 1 (2024): 155.

[3] R. D. Treede, W. Rief, A. Barke, et al., “Chronic Pain as a Symptom or a Disease: The IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11),” Pain 160, no. 1 (2019): 19-27.

[4] C. Sommer and H. Rittner, “Pain Research in 2023: Towards Understanding Chronic Pain,” Lancet Neurology 23, no. 1 (2024): 27-28.

[5] G. Collaborators, “Global, Regional, and National Burden of Low Back Pain, 1990-2020, Its Attributable Risk Factors, and Projections to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021,” The Lancet Rheumatology 5, no. 6 (2023): e316-e329.

[6] G. B. D. Diseases and C. Injuries, “Global Incidence, Prevalence, Years Lived With Disability (YLDs), Disability-adjusted Life-years (DALYs), and Healthy Life Expectancy (HALE) for 371 Diseases and Injuries in 204 Countries and territories and 811 Subnational Locations, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021,” Lancet 403, no. 10440 (2024): 2133-2161.

[7] S. P. Cohen, L. Vase, and W. M. Hooten, “Chronic Pain: An Update on Burden, Best Practices, and New Advances,” Lancet 397, no. 10289 (2021): 2082-2097.

[8] J. L. St Sauver, D. O. Warner, B. P. Yawn, et al., “Why Patients Visit Their Doctors: Assessing the Most Prevalent Conditions in a Defined American Population,” Mayo Clinic Proceedings 88, no. 1 (2013): 56-67.

[9] D. Vardeh, R. J. Mannion, and C. J. Woolf, “Toward a Mechanism-Based Approach to Pain Diagnosis,” The Journal of Pain 17 (2016): T50-T69. 9 Suppl.

[10] J. Nijs, A. Lahousse, C. Fernandez-de-Las-Penas, et al., “Towards Precision Pain Medicine for Pain After Cancer: The Cancer Pain Phenotyping Network Multidisciplinary International Guidelines for Pain Phenotyping Using Nociplastic Pain Criteria,” British Journal of Anaesthesia 130, no. 5 (2023): 611-621.

[11] E. Kosek, D. Clauw, J. Nijs, et al., “Chronic Nociplastic Pain Affecting the Musculoskeletal System: Clinical Criteria and Grading System,” Pain 162, no. 11 (2021): 2629-2634.

[12] A. Jain, S. Hakim, and C. J. Woolf. Immune Drivers of Physiological and Pathological Pain. Journal of Experimental Medicine 2024; 221(5): e20221687.

[13] A. M. Drewes, A. E. Olesen, A. D. Farmer, E. Szigethy, V. Rebours, and S. S. Olesen, “Gastrointestinal Pain,” Nature reviews Disease primers 6, no. 1 (2020): 1.

[14] A. M. Paez-Hurtado and C. A. Calderon-Ospina, N.-M. MO, “Mechanisms of Action of Vitamin B1 (thiamine), B6 (pyridoxine), and B12 (cobalamin) in Pain: A Narrative Review,” Nutritional Neuroscience 26, no. 3 (2023): 235-253.

[15] K. Toda, “Pure Nociceptive Pain Is Very Rare,” Current Medical Research and Opinion 35, no. 11 (2019): 1991.

[16] R. Freynhagen, H. A. Parada, C. A. Calderon-Ospina, et al., “Current Understanding of the Mixed Pain Concept: A Brief Narrative Review,” Current Medical Research and Opinion 35, no. 6 (2019): 1011-1018.

[17] S. Ghazisaeidi, M. M. Muley, and M. W. Salter, “Neuropathic Pain: Mechanisms, Sex Differences, and Potential Therapies for a Global Problem,” Annual Review of Pharmacology and Toxicology 63 (2023): 565-583.

[18] L. Colloca, T. Ludman, D. Bouhassira, et al., “Neuropathic Pain,” Nature reviews Disease primers 3 (2017): 17002.

[19] Q. Zheng, W. Xie, D. D. Luckemeyer, et al., “Synchronized Cluster Firing, a Distinct Form of Sensory Neuron Activation, Drives Spontaneous Pain,” Neuron 110, no. 2 (2022): 209-220. e206.

[20] J. Scholz, N. B. Finnerup, N. Attal, et al., “The IASP Classification of Chronic Pain for ICD-11: Chronic Neuropathic Pain,” Pain 160, no. 1 (2019): 53-59.

[21] N. B. Finnerup, R. Kuner, and T. S. Jensen, “Neuropathic Pain: From Mechanisms to Treatment,” Physiological Reviews 101, no. 1 (2021): 259-301.

[22] S. P. Cohen and J. Mao, “Neuropathic Pain: Mechanisms and Their Clinical Implications,” Bmj 348 (2014): f7656.

[23] E. Kosek, M. Cohen, R. Baron, et al., “Do We Need a Third Mechanistic Descriptor for Chronic Pain States?,” Pain 157, no. 7 (2016): 1382-1386.

[24] C. M. Kaplan, E. Kelleher, A. Irani, A. Schrepf, D. J. Clauw, and S. E. Harte, “Deciphering Nociplastic Pain: Clinical Features, Risk Factors and Potential Mechanisms,” Nature reviews Neurology 20, no. 6 (2024): 347-363.

[25] M.-A. Fitzcharles, S. P. Cohen, D. J. Clauw, G. Littlejohn, C. Usui, and W. Häuser, “Nociplastic Pain: Towards an Understanding of Prevalent Pain Conditions,” The Lancet 397, no. 10289 (2021): 2098-2110.

[26] R. Freynhagen, R. Rolke, R. Baron, et al., “Pseudoradicular and Radicular Low-back Pain-a Disease Continuum Rather Than Different Entities? Answers From Quantitative Sensory Testing,” Pain 135, no. 1-2 (2008): 65-74.

[27] M. A. Fitzcharles, S. Perrot, and W. Hauser, “Comorbid Fibromyalgia: A Qualitative Review of Prevalence and Importance,” European Journal of Pain (London, England) 22, no. 9 (2018): 1565-1576.

[28] R. R. Ji, A. Chamessian, Y. Q. Zhang, “Pain Regulation by Non-neuronal Cells and Inflammation,” Science 354, no. 6312 (2016): 572-577.

[29] M. Tanaka, N. Torok, F. Toth, and A. Szabo, L. Vecsei, “Co-Players in Chronic Pain: Neuroinflammation and the Tryptophan-Kynurenine Metabolic Pathway,” Biomedicines 9, no. 8 (2021): 897.

[30] W. Zhang, M. Lyu, N. J. Bessman, et al., “Gut-innervating Nociceptors Regulate the Intestinal Microbiota to Promote Tissue Protection,” Cell 185, no. 22 (2022): 4170-4189. e4120.

[31] L. D.H. Chen, H. Cui, J. Fang, et al., “Inflammatory Responses and Inflammation-associated Diseases in Organs,” Inflammatory Responses and inflammation-associated Diseases in Organs 9, no. 6 (2017): 7204-7218.

[32] Y. Cao, D. Fan, and Y. Yin, “Pain Mechanism in Rheumatoid Arthritis: From Cytokines to Central Sensitization,” Mediators of Inflammation 2020 (2020): 2076328.

[33] S. M. Brierley and D. R. Linden, “Neuroplasticity and Dysfunction After Gastrointestinal Inflammation,” Nature reviews Gastroenterology & hepatology 11, no. 10 (2014): 611-627.

[34] H. Chuang, E. Prescott, and H. Kong, “Bradykinin and Nerve Growth Factor Release the Capsaicin Receptor From PtdIns(4,5)P2-mediated Inhibition,” Nature 411 (2001): 957-962.

[35] C. A. Warwick, A. L. Keyes, T. M. Woodruff, and Y. M. Usachev, “The Complement Cascade in the Regulation of Neuroinflammation, Nociceptive Sensitization, and Pain,” Journal of Biological Chemistry 297, no. 3 (2021): 101085.

[36] N. Ghasemlou, I. M. Chiu, J. P. Julien, and C. J. Woolf, “CD11b+Ly6G- myeloid Cells Mediate Mechanical Inflammatory Pain Hypersensitivity,” PNAS 112, no. 49 (2015): E6808-6817.

[37] P. Starkl, G. Jonsson, T. Artner, et al., “Mast Cell-derived BH4 Is a Critical Mediator of Postoperative Pain,” BioRxiv (2023).

[38] B. C. Jiang, T. Liu, and Y. J. Gao, “Chemokines in Chronic Pain: Cellular and Molecular Mechanisms and Therapeutic Potential,” Pharmacology & Therapeutics 212 (2020): 107581.

[39] J. R. Silva, M. Iftinca, F. I. Fernandes Gomes, et al., “Skin-resident Dendritic Cells Mediate Postoperative Pain via CCR4 on Sensory Neurons,” PNAS 119, no. 4 (2022): e2118238119.

[40] O. Chen, C. R. Donnelly, and R. R. Ji, “Regulation of Pain by Neuro-immune Interactions Between Macrophages and Nociceptor Sensory Neurons,” Current Opinion in Neurobiology 62 (2020): 17-25.

[41] M. van der Vlist, R. Raoof, H. Willemen, et al., “Macrophages Transfer Mitochondria to Sensory Neurons to Resolve Inflammatory Pain,” Neuron 110, no. 4 (2022): 613-626. e619.

[42] X. Zhang, J. Huang, and P. A. McNaughton, “NGF Rapidly Increases Membrane Expression of TRPV1 Heat-gated Ion Channels,” Embo Journal 24, no. 24 (2005): 4211-4223.

[43] J. V. Priestley, G. J. Michael, S. Averill, M. Liu, and N. Willmott, “Regulation of Nociceptive Neurons by Nerve Growth Factor and Glial Cell Line Derived Neurotrophic Factor,” Canadian Journal of Physiology and Pharmacology 80, no. 5 (2002): 495-505.

[44] S. Y. Park, J. Y. Choi, R. U. Kim, Y. S. Lee, H. J. Cho, and D. S. Kim, “Downregulation of Voltage-gated Potassium Channel α Gene Expression by Axotomy and Neurotrophins in Rat Dorsal Root Ganglia,” Molecules and Cells 16, no. 2 (2003): 256-259.

[45] R. Jha, J. D. Bernstock, J. I. Chalif, et al., “Updates on Pathophysiology of Discogenic Back Pain,” Journal of Clinical Medicine 12, no. 21 (2023): 6907.

[46] S. P. Raychaudhuri, S. K. Raychaudhuri, K. R. Atkuri, L. A. Herzenberg, and L. A. Herzenberg, “Nerve Growth Factor: A Key Local Regulator in the Pathogenesis of Inflammatory Arthritis,” Arthritis and Rheumatism 63, no. 11 (2011): 3243-3252.

[47] D. Y. Liang, X. Li, X. Shi, et al., “The Complement Component C5a Receptor Mediates Pain and Inflammation in a Postsurgical Pain Model,” Pain 153, no. 2 (2012): 366-372.

[48] C. R. Donnelly, C. Jiang, A. S. Andriessen, et al., “STING Controls Nociception via Type I Interferon Signalling in Sensory Neurons,” Nature 591, no. 7849 (2021): 275-280.

[49] P. Barragan-Iglesias, U. Franco-Enzastiga, V. Jeevakumar, et al., “Type I Interferons Act Directly on Nociceptors to Produce Pain Sensitization: Implications for Viral Infection-Induced Pain,” Journal of Neuroscience 40, no. 18 (2020): 3517-3532.

[50] C. Wong, O. Barkai, F. Wang, et al., “mTORC2 mediates Structural Plasticity in Distal Nociceptive Endings That Contributes to Pain Hypersensitivity Following Inflammation,” Journal of Clinical Investigation 132, no. 15 (2022): e152635.

[51] T. Masuoka, Y. Yamashita, J. Yoshida, et al., “Sensitization of Glutamate Receptor-mediated Pain Behaviour via Nerve Growth Factor-dependent Phosphorylation of Transient Receptor Potential V1 Under Inflammatory Conditions,” British Journal of Pharmacology 177, no. 18 (2020): 4223-4241.

[52] S. Zhang, B. Hu, W. Liu, et al., “The Role of Structure and Function Changes of Sensory Nervous System in Intervertebral Disc-related Low Back Pain,” Osteoarthritis and Cartilage 29, no. 1 (2021): 17-27.

[53] W. Li, Y. Gong, J. Liu, et al., “Peripheral and Central Pathological Mechanisms of Chronic Low Back Pain: A Narrative Review,” J Pain Res 14 (2021): 1483-1494.

[54] Y. Kawasaki, L. Zhang, J. K. Cheng, and R. R. Ji, “Cytokine Mechanisms of central Sensitization: Distinct and Overlapping Role of Interleukin-1beta, Interleukin-6, and Tumor Necrosis Factor-alpha in Regulating Synaptic and Neuronal Activity in the Superficial Spinal Cord,” Journal of Neuroscience 28, no. 20 (2008): 5189-5194.

[55] M. Simonetti, A. M. Hagenston, D. Vardeh, et al., “Nuclear Calcium Signaling in Spinal Neurons Drives a Genomic Program Required for Persistent Inflammatory Pain,” Neuron 77, no. 1 (2013): 43-57.

[56] J. A. Vega, O. Garcia-Suarez, J. Hannestad, M. Perez-Perez, and A. Germana, “Neurotrophins and the Immune System,” Journal of Anatomy 203, no. 1 (2003): 1-19.

[57] A. J. Freemont, A. Watkins, and C. Le Maitre, “Nerve Growth Factor Expression and Innervation of the Painful Intervertebral Disc,” Journal of Pathology 197, no. 3 (2002): 286-292.

[58] D. Purmessur, A. J. Freemont, and J. A. Hoyland, “Expression and Regulation of Neurotrophins in the Nondegenerate and Degenerate human Intervertebral Disc,” Arthritis Research & Therapy 10, no. 4 (2008): R99.

[59] A. D. Diwan and J. Melrose, “Intervertebral Disc Degeneration and How It Leads to Low Back Pain,” JOR Spine 6, no. 1 (2023): e1231.

[60] A. N. Khan, H. E. Jacobsen, J. Khan, et al., “Inflammatory Biomarkers of Low Back Pain and Disc Degeneration: A Review,” Ann N Y Acad Sci 1410, no. 1 (2017): 68-84.

[61] K. Aso, S. M. Shahtaheri, R. Hill, D. Wilson, D. F. McWilliams, and D. A. Walsh, “Associations of Symptomatic Knee Osteoarthritis with Histopathologic Features in Subchondral Bone,” Arthritis Rheumatol 71, no. 6 (2019): 916-924.

[62] G. Goodwin and S. B. McMahon, “The Physiological Function of Different Voltage-gated Sodium Channels in Pain,” Nature Reviews Neuroscience 22, no. 5 (2021): 263-274.

[63] S. D. Dib-Hajj, Y. Yang, J. A. Black, and S. G. Waxman, “The Na(V)1.7 Sodium Channel: From Molecule to Man,” Nature Reviews Neuroscience 14, no. 1 (2013): 49-62.

[64] S. D. Dib-Hajj, J. A. Black, and S. G. Waxman, “NaV1.9: A Sodium Channel Linked to human Pain,” Nature Reviews Neuroscience 16, no. 9 (2015): 511-519.

[65] G. P. Higerd-Rusli, S. Tyagi, C. A. Baker, et al., “Inflammation Differentially Controls Transport of Depolarizing Nav versus Hyperpolarizing Kv Channels to Drive Rat Nociceptor Activity,” PNAS 120, no. 11 (2023): e2215417120.

[66] R. Zhou, W. Fu, D. Vasylyev, S. G. Waxman, and C. J. Liu, “Ion Channels in Osteoarthritis: Emerging Roles and Potential Targets,” Nat Rev Rheumatol 20, no. 9 (2024): 545-564.

[67] J. J. Cox, F. Reimann, A. K. Nicholas, et al., “An SCN9A Channelopathy Causes Congenital Inability to Experience Pain,” Nature 444, no. 7121 (2006): 894-898.

[68] M. Cha, H. Bak, B. H. Lee, and J. H. Jang, “Alleviation of Peripheral Sensitization by Quadriceps Insertion of Cog Polydioxanone filaments in Knee Osteoarthritis Rats,” Biochemical and Biophysical Research Communications 698 (2024): 149549.

[69] S. G. Waxman, “Targeting a Peripheral Sodium Channel to Treat Pain,” The New Engl and Journal of Medicine 389, no. 5 (2023): 466-469.

[70] S. J. Guo, Y. Q. Shi, Y. N. Zheng, H. Liu, and Y. L. Zheng, “The Voltage-Gated Calcium Channel alpha2delta Subunit in Neuropathic Pain,” Molecular Neurobiology (2024).

[71] X. Chen, D. Liu, D. Zhou, et al., “Small-molecule Ca(V)Alpha(1)⋅Ca(V)Beta Antagonist Suppresses Neuronal Voltage-gated Calcium-channel Trafficking,” PNAS 115, no. 45 (2018): E10566-E10575.

[72] S. Adaes, J. Ferreira-Gomes, M. Mendonca, L. Almeida, J. M. Castro-Lopes, and F. L. Neto, “Injury of Primary Afferent Neurons May Contribute to Osteoarthritis Induced Pain: An Experimental Study Using the Collagenase Model in Rats,” Osteoarthritis and Cartilage 23, no. 6 (2015): 914-924.

[73] L. Sun, G. Wang, M. He, Z. Mei, F. Zhang, and P. Liu, “Effect and Mechanism of the CACNA2D1-CGRP Pathway in Osteoarthritis-induced Ongoing Pain,” Biomedicine & Pharmacotherapy 129 (2020): 110374.

[74] K. E. Rose, N. Lunardi, A. Boscolo, et al., “Immunohistological Demonstration of CaV3.2 T-type Voltage-gated Calcium Channel Expression in Soma of Dorsal Root Ganglion Neurons and Peripheral Axons of Rat and Mouse,” Neuroscience 250 (2013): 263-274.

[75] J. Su, T. Gao, T. Shi, et al., “Phenotypic Changes in Dorsal Root Ganglion and Spinal Cord in the Collagen Antibody-induced Arthritis Mouse Model,” Journal of Comparative Neurology 523, no. 10 (2015): 1505-1528.

[76] E. Krock, A. Jurczak, and C. I. Svensson, “Pain Pathogenesis in Rheumatoid Arthritis-what Have We Learned From Animal Models?,” Pain 159 (2018): S98-S109. Suppl 1.

[77] D. B. Bas, J. Su, K. Sandor, et al., “Collagen Antibody-induced Arthritis Evokes Persistent Pain With Spinal Glial Involvement and Transient Prostaglandin Dependency,” Arthritis and Rheumatism 64, no. 12 (2012): 3886-3896.

[78] L. Hoppanova and L. Lacinova, “Voltage-dependent Ca(V)3.2 and Ca(V)2.2 Channels in Nociceptive Pathways,” Pflugers Archiv: European journal of physiology 474, no. 4 (2022): 421-434.

[79] A. Garcia-Caballero, V. M. Gadotti, P. Stemkowski, et al., “The Deubiquitinating Enzyme USP5 Modulates Neuropathic and Inflammatory Pain by Enhancing Cav3.2 Channel Activity,” Neuron 83, no. 5 (2014): 1144-1158.

[80] B. Itson-Zoske, S. M. Shin, H. Xu, et al., “Selective Block of Sensory Neuronal T-type/Cav3.2 Activity Mitigates Neuropathic Pain Behavior in a Rat Model of Osteoarthritis Pain,” Arthritis Research & Therapy 24, no. 1 (2022): 168.

[81] K. J. Blake, P. Baral, T. Voisin, et al., “Staphylococcus aureus Produces Pain Through Pore-forming Toxins and Neuronal TRPV1 That Is Silenced by QX-314,” Nature Communications 9, no. 1 (2018): 37.

[82] J. Reyes-García, A. Carbajal-García, and L. M. Montaño, “Transient Receptor Potential Cation Channel Subfamily V (TRPV) and Its Importance in Asthma,” European Journal of Pharmacology 915 (2022): 174692.

[83] M. Zhang, Y. Ma, X. Ye, N. Zhang, L. Pan, and B. Wang, “TRP (transient receptor potential) Ion Channel family: Structures, Biological Functions and Therapeutic Interventions for Diseases,” Signal Transduct Target Ther 8, no. 1 (2023): 261.

[84] L. Basso and C. Altier, “Transient Receptor Potential Channels in Neuropathic Pain,” Current Opinion in Pharmacology 32 (2017): 9-15.

[85] T. Galindo, J. Reyna, and A. Weyer, “Evidence for Transient Receptor Potential (TRP) Channel Contribution to Arthritis Pain and Pathogenesis,” Pharmaceuticals (Basel, Switzerland) 11, no. 4 (2018): 105.

[86] G. Goncalves Dos Santos, R. Li, and M. P. E. Ng, “CB(1) Receptor-dependent Desensitisation of TRPV1 Channels Contributes to the Analgesic Effect of Dipyrone in Sensitised Primary Sensory Neurons,” British Journal of Pharmacology 177, no. 20 (2020): 4615-4626.

[87] R. Xing, P. Wang, L. Zhao, B. Xu, N. Zhang, and X. Li, “Mechanism of TRPA1 and TRPV4 Participating in Mechanical Hyperalgesia of Rat Experimental Knee Osteoarthritis,” Archives of Rheumatology 32, no. 2 (2017): 96-104.

[88] M. Soga, T. Izumi, I. Nanchi, et al., “Suppression of Joint Pain in Transient Receptor Potential Vanilloid 4 Knockout Rats With Monoiodoacetate-induced Osteoarthritis,” Pain Rep 6, no. 3 (2021): e951.

[89] K. Talavera, J. B. Startek, J. Alvarez-Collazo, et al., “Mammalian Transient Receptor Potential TRPA1 Channels: From Structure to Disease,” Physiological Reviews 100, no. 2 (2020): 725-803.

[90] Z. Zhang, J. Yao, J. Huo, et al., “Action Potential-independent Spontaneous Microdomain Ca(2+) Transients-mediated Continuous Neurotransmission Regulates Hyperalgesia,” PNAS 122, no. 3 (2025): e2406741122.

[91] D. Souza Monteiro de Araujo, R. Nassini, P. Geppetti, and F. De Logu, “TRPA1 as a Therapeutic Target for Nociceptive Pain,” Expert Opinion on Therapeutic Targets 24, no. 10 (2020): 997-1008.

[92] R. L. Silva, A. H. Lopes, R. M. Guimarães, and T. M. Cunha, “CXCL1/CXCR2 signaling in Pathological Pain: Role in Peripheral and central Sensitization,” Neurobiology of Disease 105 (2017): 109-116.

[93] M. K. Chung, J. Asgar, J. Lee, M. S. Shim, C. Dumler, and J. Y. Ro, “The Role of TRPM2 in Hydrogen Peroxide-induced Expression of Inflammatory Cytokine and Chemokine in Rat Trigeminal Ganglia,” Neuroscience 297 (2015): 160-169.

[94] K. Haraguchi, A. Kawamoto, K. Isami, et al., “TRPM2 contributes to Inflammatory and Neuropathic Pain Through the Aggravation of Pronociceptive Inflammatory Responses in Mice,” Journal of Neuroscience 32, no. 11 (2012): 3931-3941.

[95] A. Sadowska, W. Hitzl, A. Karol, et al., “Differential Regulation of TRP Channel Gene and Protein Expression by Intervertebral Disc Degeneration and Back Pain,” Scientific Reports 9, no. 1 (2019): 18889.

[96] R. Ramachandran, E. Hyun, L. Zhao, et al., “TRPM8 activation Attenuates Inflammatory Responses in Mouse Models of Colitis,” PNAS 110, no. 18 (2013): 7476-7481.

[97] K. M. Alawi, F. A. Russell, A. A. Aubdool, et al., “Transient Receptor Potential Canonical 5 (TRPC5) Protects Against Pain and Vascular Inflammation in Arthritis and Joint Inflammation,” Annals of the Rheumatic Diseases 76, no. 1 (2017): 252-260.

[98] J. de Sousa Valente, K. M. Alawi, P. Keringer, et al., “Examining the Role of Transient Receptor Potential Canonical 5 (TRPC5) in Osteoarthritis,” Osteoarthr Cartil Open 2, no. 4 (2020): 100119.

[99] C. Tsantoulas, “Emerging Potassium Channel Targets for the Treatment of Pain,” Current opinion in supportive and palliative care 9, no. 2 (2015): 147-154.

[100] J. E. Linley, K. Rose, M. Patil, B. Robertson, A. N. Akopian, and N. Gamper, “Inhibition of M Current in Sensory Neurons by Exogenous Proteases: A Signaling Pathway Mediating Inflammatory Nociception,” Journal of Neuroscience 28, no. 44 (2008): 11240-11249.

[101] W. Xu, Y. Wu, Y. Bi, L. Tan, Y. Gan, and K. Wang, “Activation of Voltage-gated KCNQ/Kv7 Channels by Anticonvulsant Retigabine Attenuates Mechanical Allodynia of Inflammatory Temporomandibular Joint in Rats,” Mol Pain 6 (2010): 49.

[102] G. M. Passmore, A. A. Selyanko, M. Mistry, et al., “KCNQ/M Currents in Sensory Neurons: Significance for Pain Therapy,” Journal of Neuroscience 23, no. 18 (2003): 7227-7236.

[103] F. Zhang, Y. Liu, D. Zhang, X. Fan, D. Shao, and H. Li, “Suppression of KCNQ/M Potassium Channel in Dorsal Root Ganglia Neurons Contributes to the Development of Osteoarthritic Pain,” Pharmacology 103, no. 5-6 (2019): 257-262.

[104] H. Hayashi, M. Iwata, N. Tsuchimori, and T. Matsumoto, “Activation of Peripheral KCNQ Channels Attenuates Inflammatory Pain,” Mol Pain 10 (2014): 15.

[105] I. Szelenyi, “Flupirtine, a Re-discovered Drug, Revisited,” Inflammation Research 62, no. 3 (2013): 251-258.

[106] A. Peretz, N. Degani, R. Nachman, et al., “Meclofenamic Acid and Diclofenac, Novel Templates of KCNQ2/Q3 Potassium Channel Openers, Depress Cortical Neuron Activity and Exhibit Anticonvulsant Properties,” Molecular Pharmacology 67, no. 4 (2005): 1053-1066.

[107] R. Lu, R. Lukowski, M. Sausbier, et al., “BKCa Channels Expressed in Sensory Neurons Modulate Inflammatory Pain in Mice,” Pain 155, no. 3 (2014): 556-565.

[108] C. Flauaus, P. Engel, F. Zhou, et al., “Slick Potassium Channels Control Pain and Itch in Distinct Populations of Sensory and Spinal Neurons in Mice,” Anesthesiology 136, no. 5 (2022): 802-822.

[109] S. A. Heusser and S. A. Pless, “Acid-sensing Ion Channels as Potential Therapeutic Targets,” Trends in Pharmacological Sciences 42, no. 12 (2021): 1035-1050.

[110] J. Karczewski, R. H. Spencer, V. M. Garsky, et al., “Reversal of Acid-induced and Inflammatory Pain by the Selective ASIC3 Inhibitor, APETx2,” British Journal of Pharmacology 161, no. 4 (2010): 950-960.

[111] R. C. Jones, L. Xu, and G. F. Gebhart, “The Mechanosensitivity of Mouse Colon Afferent Fibers and Their Sensitization by Inflammatory Mediators Require Transient Receptor Potential Vanilloid 1 and Acid-sensing Ion Channel 3,” Journal of Neuroscience 25, no. 47 (2005): 10981-10989.

[112] T. Lynagh, J. L. Romero-Rojo, C. Lund, S. A. Pless, “Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen,” Journal of Medicinal Chemistry 60, no. 19 (2017): 8192-8200.

[113] N. Voilley, J. de Weille, J. Mamet, and M. Lazdunski, “Nonsteroid Anti-Inflammatory Drugs Inhibit both the Activity and the Inflammation-Induced Expression of Acid-Sensing Ion Channels in Nociceptors,” Journal of Neuroscience 21, no. 20 (2001): 8026-8033.

[114] M. Niibori, Y. Kudo, T. Hayakawa, et al., “Mechanism of Aspirin-induced Inhibition on the Secondary Hyperalgesia in Osteoarthritis Model Rats,” Heliyon 6, no. 5 (2020): e03963.

[115] N. G. Jones, R. Slater, H. Cadiou, P. McNaughton, and S. B. McMahon, “Acid-induced Pain and Its Modulation in Humans,” Journal of Neuroscience 24, no. 48 (2004): 10974-10979.

[116] A. K. Gupta, D. Parasar, A. Sagar, et al., “Analgesic and Anti-Inflammatory Properties of Gelsolin in Acetic Acid Induced Writhing, Tail Immersion and Carrageenan Induced Paw Edema in Mice,” PLoS ONE 10, no. 9 (2015): e0135558.

[117] Y. Jiang, X. Yang, J. Jiang, and B. Xiao, “Structural Designs and Mechanogating Mechanisms of the Mechanosensitive Piezo Channels,” Trends in Biochemical Sciences 46, no. 6 (2021): 472-488.

[118] B. Coste, J. Mathur, M. Schmidt, et al., “Piezo1 and Piezo2 Are Essential Components of Distinct Mechanically Activated Cation Channels,” Science 330, no. 6000 (2010): 55-60.

[119] M. L.J. Szczot, N. Ghitani, A. Barik, et al., “PIEZO2 mediates Injury-induced Tactile Pain in Mice and Humans,” SCIENCE TRANSLATIONAL MEDICINE 10, no. 462 (2018): eaat9892.

[120] A. M. Obeidat, M. J. Wood, N. S. Adamczyk, et al., “Piezo2 expressing Nociceptors Mediate Mechanical Sensitization in Experimental Osteoarthritis,” Nature Communications 14, no. 1 (2023): 2479.

[121] K. Inoue, “The Role of ATP Receptors in Pain Signaling,” Neurochemical Research 47, no. 9 (2022): 2454-2468.

[122] L. Y. Wang, W. Q. Cai, P. H. Chen, Q. Y. Deng, and C. M. Zhao, “Downregulation of P2×7 Receptor Expression in Rat Oligodendrocyte Precursor Cells After Hypoxia Ischemia,” Glia 57, no. 3 (2009): 307-319.

[123] G. Dell'Antonio, A. Quattrini, E. Dal Cin, A. Fulgenzi, and M. E. Ferrero, “Antinociceptive Effect of a New P(2Z)/P2×7 Antagonist, Oxidized ATP, in Arthritic Rats,” Neuroscience Letters 327, no. 2 (2002): 87-90.

[124] Y. Dai, T. Fukuoka, H. Wang, et al., “Contribution of Sensitized P2X Receptors in Inflamed Tissue to the Mechanical Hypersensitivity Revealed by Phosphorylated ERK in DRG Neurons,” Pain 108, no. 3 (2004): 258-266.

[125] C. Wang, G. W. Li, and L. Y. Huang, “Prostaglandin E2 Potentiation of P2×3 Receptor Mediated Currents in Dorsal Root Ganglion Neurons,” Mol Pain 3 (2007): 22.

[126] M. B.N. Mousseau, K. Y. Lee, H. Leduc-Pessah, et al., “Microglial Pannexin-1 Channel Activation Is a Spinal Determinant of Joint Pain,” Science Advances 4, no. 8 (2018): eaas9846.

[127] T. C. Stock, B. J. Bloom, N. Wei, et al., “Efficacy and Safety of CE-224,535, an Antagonist of P2×7 Receptor, in Treatment of Patients With Rheumatoid Arthritis Inadequately Controlled by Methotrexate,” The Journal of Rheumatology 39, no. 4 (2012): 720-727.

[128] E. C. Keystone, M. M. Wang, M. Layton, S. Hollis, I. B. McInnes, and D. C. S. Team, “Clinical Evaluation of the Efficacy of the P2×7 Purinergic Receptor Antagonist AZD9056 on the Signs and Symptoms of Rheumatoid Arthritis in Patients With Active Disease Despite Treatment With Methotrexate or Sulphasalazine,” Annals of the Rheumatic Diseases 71, no. 10 (2012): 1630-1635.

[129] A. Eser, J. F. Colombel, P. Rutgeerts, et al., “Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2×7 in Adult Patients With Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study,” Inflammatory Bowel Diseases 21, no. 10 (2015): 2247-2253.

[130] B. Hechler and C. Gachet, “Purinergic Receptors in Thrombosis and Inflammation,” Arteriosclerosis, Thrombosis, and Vascular Biology 35, no. 11 (2015): 2307-2315.

[131] W. J. Zhang, M. Y. Li, C. Y. Wang, et al., “P2Y12 receptor Involved in the Development of Chronic Nociceptive Pain as a Sensory Information Mediator,” Biomedicine & Pharmacotherapy 164 (2023): 114975.

[132] I. von Kügelgen, “Pharmacology of P2Y Receptors,” Brain Research Bulletin 151 (2019): 12-24.

[133] A. Gómez Morillas, V. C. Besson, and D. Lerouet, “Microglia and Neuroinflammation: What Place for P2RY12?,” International Journal of Molecular Sciences 22, no. 4 (2021): 8026-8033.

[134] M. Defaye, N. S. Abdullah, M. Iftinca, et al., “Gut-innervating TRPV1+ Neurons Drive Chronic Visceral Pain via Microglial P2Y12 Receptor,” Cellular and Molecular Gastroenterology and Hepatology 13, no. 4 (2022): 977-999.

[135] C. Y. Fan, B. B. McAllister, S. Stokes-Heck, et al., “Divergent Sex-specific Pannexin-1 Mechanisms in Microglia and T Cells Underlie Neuropathic Pain,” Neuron 113, no. 6 (2025): 896-911.

[136] K. W. Li, Y. P. Yu, C. Zhou, et al., “Calcium Channel α2δ1 Proteins Mediate Trigeminal Neuropathic Pain States Associated With Aberrant Excitatory Synaptogenesis,” Journal of Biological Chemistry 289, no. 10 (2014): 7025-7037.

[137] C. S. Bauer, M. Nieto-Rostro, W. Rahman, et al., “The Increased Trafficking of the Calcium Channel Subunit alpha2delta-1 to Presynaptic Terminals in Neuropathic Pain Is Inhibited by the alpha2delta Ligand Pregabalin,” Journal of Neuroscience 29, no. 13 (2009): 4076-4088.

[138] J. Park, Y. P. Yu, C. Y. Zhou, et al., “Central Mechanisms Mediating Thrombospondin-4-induced Pain States,” Journal of Biological Chemistry 291, no. 25 (2016): 13335-13348.

[139] A. Kamalova and T. Nakagawa, “AMPA Receptor Structure and Auxiliary Subunits,” The Journal of Physiology 599, no. 2 (2021): 453-469.

[140] J. Chen, L. Li, S. R. Chen, et al., “The alpha2delta-1-NMDA Receptor Complex Is Critically Involved in Neuropathic Pain Development and Gabapentin Therapeutic Actions,” Cell reports 22, no. 9 (2018): 2307-2321.

[141] M. Nieto-Rostro, K. Ramgoolam, W. S. Pratt, A. Kulik, and A. C. Dolphin, “Ablation of α(2)δ-1 Inhibits Cell-surface Trafficking of Endogenous N-type Calcium Channels in the Pain Pathway in Vivo,” PNAS 115, no. 51 (2018): E12043-e12052.

[142] F. X. Zhang, V. M. Gadotti, I. A. Souza, L. Chen, and G. W. Zamponi, “BK Potassium Channels Suppress Cavalpha2delta Subunit Function to Reduce Inflammatory and Neuropathic Pain,” Cell reports 22, no. 8 (2018): 1956-1964.

[143] K. A. Beeson, R. Beeson, G. L. Westbrook, and E. Schnell, “α2δ-2 Protein Controls Structure and Function at the Cerebellar Climbing Fiber Synapse,” Journal of Neuroscience 40, no. 12 (2020): 2403-2415.

[144] S. Geisler, C. L. Schopf, R. Stanika, et al., “Presynaptic Alpha(2)Delta-2 Calcium Channel Subunits Regulate Postsynaptic GABA(A) Receptor Abundance and Axonal Wiring,” Journal of Neuroscience 39, no. 14 (2019): 2581-2605.

[145] Y. Li, C. E. Tatsui, L. D. Rhines, et al., “Dorsal Root Ganglion Neurons Become Hyperexcitable and Increase Expression of Voltage-gated T-type Calcium Channels (Cav3.2) in Paclitaxel-induced Peripheral Neuropathy,” Pain 158, no. 3 (2017): 417-429.

[146] M. Sleczkowska, K. Misra, S. Santoro, M. M. Gerrits, J. G. J. Hoeijmakers, and PainNet Study G, “Ion Channel Genes in Painful Neuropathies,” Biomedicines 11, no. 10 (2023): 2680.

[147] A. D. Mickle, A. J. Shepherd, and D. P. Mohapatra, “Sensory TRP Channels: The Key Transducers of Nociception and Pain,” Progress in Molecular Biology and Translational Science 131 (2015): 73-118.

[148] K. Meacham, A. Shepherd, D. P. Mohapatra, and S. Haroutounian, “Neuropathic Pain: Central vs. Peripheral Mechanisms,” Current Pain and Headache Reports 21, no. 6 (2017): 28.

[149] H. Wang, T. Song, W. Wang, and Z. Zhang, “TRPM2 participates the Transformation of Acute Pain to Chronic Pain During Injury-induced Neuropathic Pain,” Synapse 73, no. 10 (2019): e22117.

[150] A. Marcotti, J. Fernandez-Trillo, A. Gonzalez, et al., “TRPA1 modulation by Sigma-1 Receptor Prevents Oxaliplatin-induced Painful Peripheral Neuropathy,” Brain 146, no. 2 (2023): 475-491.

[151] F. De Logu, G. De Siena, L. Landini, et al., “Non-neuronal TRPA1 Encodes Mechanical Allodynia Associated With Neurogenic Inflammation and Partial Nerve Injury in Rats,” British Journal of Pharmacology 180, no. 9 (2023): 1232-1246.

[152] M. Marchi, E. Salvi, M. Andelic, et al., “TRPA1 rare Variants in Chronic Neuropathic and Nociplastic Pain Patients,” Pain 164, no. 9 (2023): 2048-2059.

[153] M. Nazıroğlu, “Activation of TRPM2 and TRPV1 Channels in Dorsal Root Ganglion by NADPH Oxidase and Protein Kinase C Molecular Pathways: A Patch Clamp Study,” Journal of Molecular Neuroscience : MN 61, no. 3 (2017): 425-435.

[154] V. D. Aloi, S. Pinto, R. Van Bree, K. Luyten, T. Voets, and J. Vriens, “TRPM3 as a Novel Target to Alleviate Acute Oxaliplatin-induced Peripheral Neuropathic Pain,” Pain 164, no. 9 (2023): 2060-2069.

[155] C. Martín-Escura, A. Medina-Peris, L. A. Spear, et al., “β-Lactam TRPM8 Antagonist RGM8-51 Displays Antinociceptive Activity in Different Animal Models,” International Journal of Molecular Sciences 23, no. 5 (2022): 2692.

[156] P. Gormley, V. Anttila, B. S. Winsvold, et al., “Meta-analysis of 375,000 Individuals Identifies 38 Susceptibility Loci for Migraine,” Nature Genetics 48, no. 8 (2016): 856-866.

[157] R. Gualdani, J. H. Yuan, P. R. Effraim, et al., “Trigeminal Neuralgia TRPM8 Mutation: Enhanced Activation, Basal [Ca(2+)](i) and Menthol Response,” Neurology Genetics 7, no. 1 (2021): e550.

[158] A. M. Bagnell, C. J. Sumner, and B. A. McCray, “TRPV4: A Trigger of Pathological RhoA Activation in Neurological Disease,” BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology 44, no. 6 (2022): e2100288.

[159] X. Hu, L. Du, S. Liu, et al., “A TRPV4-dependent Neuroimmune Axis in the Spinal Cord Promotes Neuropathic Pain,” Journal of Clinical Investigation 133, no. 5 (2023): e161507.

[160] S. Deng, S. M. E. Feely, Y. Shi, et al., “Incidence and Clinical Features of TRPV4-Linked Axonal Neuropathies in a USA Cohort of Charcot-Marie-Tooth Disease Type 2,” Neuromolecular Medicine 22, no. 1 (2020): 68-72.

[161] N. Gao, M. Li, W. Wang, Z. Liu, and Y. Guo, “The Dual Role of TRPV1 in Peripheral Neuropathic Pain: Pain Switches Caused by Its Sensitization or Desensitization,” Front Mol Neurosci 17 (2024): 1400118.

[162] J. Borzan, C. Zhao, R. A. Meyer, and S. N. Raja, “A Role for Acid-sensing Ion Channel 3, but Not Acid-sensing Ion Channel 2, in Sensing Dynamic Mechanical Stimuli,” Anesthesiology 113, no. 3 (2010): 647-654.

[163] K. Hori, N. Ozaki, S. Suzuki, and Y. Sugiura, “Upregulations of P2X(3) and ASIC3 Involve in Hyperalgesia Induced by Cisplatin Administration in Rats,” Pain 149, no. 2 (2010): 393-405.

[164] S. Diochot, A. Alloui, P. Rodrigues, et al., “Analgesic Effects of Mambalgin Peptide Inhibitors of Acid-sensing Ion Channels in Inflammatory and Neuropathic Pain,” Pain 157, no. 3 (2016): 552-559.

[165] C. C. Kung, Y. C. Huang, T. Y. Hung, C. Y. Teng, T. Y. Lee, and W. H. Sun, “Deletion of Acid-Sensing Ion Channel 3 Relieves the Late Phase of Neuropathic Pain by Preventing Neuron Degeneration and Promoting Neuron Repair,” Cells 9, no. 11 (2020): 2355.

[166] B. Yang and N. Yu, “Traditional Chinese Medicine Alleviating Neuropathic Pain Targeting Purinergic Receptor P2 in Purinergic Signaling: A Review,” Brain Research Bulletin 204 (2023): 110800.

[167] X. Zhang and G. Li, “P2Y receptors in Neuropathic Pain,” Pharmacology Biochemistry and Behavior 186 (2019): 172788.

[168] E. Fabbretti, “P2×3 receptors Are Transducers of Sensory Signals,” Brain Research Bulletin 151 (2019): 119-124.

[169] J. M. Teixeira, C. A. Parada, and C. H. Tambeli, “P2×3 and P2×2/3 Receptors Activation Induces Articular Hyperalgesia by an Indirect Sensitization of the Primary Afferent Nociceptor in the Rats' knee Joint,” European Journal of Pharmacology 879 (2020): 173054.

[170] S. Beggs and M. W. Salter, “The Known Knowns of Microglia-neuronal Signalling in Neuropathic Pain,” Neuroscience Letters 557 (2013): 37-42. Pt A.

[171] Y. Matsumura, T. Yamashita, A. Sasaki, et al., “A Novel P2×4 Receptor-selective Antagonist Produces Anti-allodynic Effect in a Mouse Model of Herpetic Pain,” Scientific Reports 6 (2016): 32461.

[172] A. Munoz, I. K. Yazdi, X. Tang, et al., “Localized Inhibition of P2×7R at the Spinal Cord Injury Site Improves Neurogenic Bladder Dysfunction by Decreasing Urothelial P2×3R Expression in Rats,” Life Sciences 171 (2017): 60-67.

[173] K. Kobayashi, H. Yamanaka, F. Yanamoto, M. Okubo, and K. Noguchi, “Multiple P2Y Subtypes in Spinal Microglia Are Involved in Neuropathic Pain After Peripheral Nerve Injury,” Glia 60, no. 10 (2012): 1529-1539.

[174] S. Wang, Z. Wang, L. Li, et al., “P2Y12 shRNA Treatment Decreases SGC Activation to Relieve Diabetic Neuropathic Pain in Type 2 Diabetes Mellitus Rats,” Journal of Cellular Physiology 233, no. 12 (2018): 9620-9628.

[175] P. Barragán-Iglesias, J. B. Pineda-Farias, M. Bravo-Hernández, et al., “Predominant Role of Spinal P2Y1 Receptors in the Development of Neuropathic Pain in Rats,” Brain Research 1636 (2016): 43-51.

[176] M. Liu and J. N. Wood, “The Roles of Sodium Channels in Nociception: Implications for Mechanisms of Neuropathic Pain,” Pain Medicine (Malden, Mass.) 12 (2011): S93-99. Suppl 3.

[177] N. Eijkelkamp, J. E. Linley, M. D. Baker, et al., “Neurological Perspectives on Voltage-gated Sodium Channels,” Brain 135 (2012): 2585-2612. Pt 9.

[178] I. Blesneac, A. C. Themistocleous, C. Fratter, et al., “Rare NaV1.7 Variants Associated With Painful Diabetic Peripheral Neuropathy,” Pain 159, no. 3 (2018): 469-480.

[179] C.-W. Huang, H.-J. Lai, P.-Y. Huang, M.-J. Lee, and C.-C. Kuo, “Anomalous Enhancement of Resurgent Na+ Currents at High Temperatures by SCN9A Mutations Underlies the Episodic Heat-enhanced Pain in Inherited Erythromelalgia,” Scientific Reports 9, no. 1 (2019): 12251.

[180] S. I. Loya-Lopez, H. N. Allen, P. Duran, et al., “Intranasal CRMP2-Ubc9 Inhibitor Regulates NaV1.7 to Alleviate Trigeminal Neuropathic Pain,” Pain (2023).

[181] Y. Xiao, C. Barbosa, Z. Pei, et al., “Increased Resurgent Sodium Currents in Nav1.8 Contribute to Nociceptive Sensory Neuron Hyperexcitability Associated With Peripheral Neuropathies,” Journal of Neuroscience 39, no. 8 (2019): 1539-1550.

[182] C. Tsantoulas and S. B. McMahon, “Opening Paths to Novel Analgesics: The Role of Potassium Channels in Chronic Pain,” Trends in Neuroscience (Tins) 37, no. 3 (2014): 146-158.

[183] F. Zhou, P. Engel, P. Ruth, R. Lukowski, A. Schmidtko, and R. Lu, “Slack Potassium Channels in Spinal Dorsal Horn Neurons Control Neuropathic Pain and Acute Itch,” Pain (2024).

[184] L. Fan, X. Guan, W. Wang, et al., “Impaired Neuropathic Pain and Preserved Acute Pain in Rats Overexpressing Voltage-gated Potassium Channel Subunit Kv1.2 in Primary Afferent Neurons,” Mol Pain 10 (2014): 8.

[185] C. Tsantoulas, L. Zhu, Y. Shaifta, et al., “Sensory Neuron Downregulation of the Kv9.1 Potassium Channel Subunit Mediates Neuropathic Pain Following Nerve Injury,” Journal of Neuroscience 32, no. 48 (2012): 17502-17513.

[186] X. Zhao, Z. Tang, H. Zhang, et al., “A Long Noncoding RNA Contributes to Neuropathic Pain by Silencing Kcna2 in Primary Afferent Neurons,” Nature Neuroscience 16, no. 8 (2013): 1024-1031.

[187] T. Yu, L. Li, H. Liu, H. Li, Z. Liu, and Z. Li, “KCNQ2/3/5 channels in Dorsal Root Ganglion Neurons Can be Therapeutic Targets of Neuropathic Pain in Diabetic Rats,” Mol Pain 14 (2018): 1744806918793229.

[188] Y. Y. Lv, H. Wang, H. T. Fan, T. Xu, W. J. Xin, and R. X. Guo, “SUMOylation of Kir7.1 Participates in Neuropathic Pain Through Regulating Its Membrane Expression in Spinal Cord Neurons,” CNS neuroscience & therapeutics 28, no. 8 (2022): 1259-1267.

[189] A. González, G. Ugarte, C. Restrepo, et al., “Role of the Excitability Brake Potassium Current I(KD) in Cold Allodynia Induced by Chronic Peripheral Nerve Injury,” Journal of Neuroscience 37, no. 12 (2017): 3109-3126.

[190] J.-T. He, X.-Y. Li, X. Zhao, and X. Liu, “Hyperpolarization-activated and Cyclic Nucleotide-gated Channel Proteins as Emerging New Targets in Neuropathic Pain,” Reviews in the Neurosciences 30, no. 6 (2019): 639-649.

[191] E. C. Emery, G. T. Young, E. M. Berrocoso, L. Chen, and P. A. McNaughton, “HCN2 ion Channels Play a central Role in Inflammatory and Neuropathic Pain,” Science 333, no. 6048 (2011): 1462-1466.

[192] F. Resta, L. Micheli, A. Laurino, et al., “Selective HCN1 Block as a Strategy to Control Oxaliplatin-induced Neuropathy,” Neuropharmacology 131 (2018): 403-413.

[193] W. Sun, F. Yang, Y. Wang, et al., “Contribution of Large-sized Primary Sensory Neuronal Sensitization to Mechanical Allodynia by Upregulation of Hyperpolarization-activated Cyclic Nucleotide Gated Channels via Cyclooxygenase 1 Cascade,” Neuropharmacology 113 (2017): 217-230. Pt A.

[194] M. Matsuda, Y. Huh, and R.-R. Ji, “Roles of Inflammation, Neurogenic Inflammation, and Neuroinflammation in Pain,” Journal of Anesthesia 33, no. 1 (2018): 131-139.

[195] N. T. Fiore, S. R. Debs, J. P. Hayes, S. S. Duffy, and G. Moalem-Taylor, “Pain-resolving Immune Mechanisms in Neuropathic Pain,” Nature reviews Neurology 19, no. 4 (2023): 199-220.

[196] A. I. Basbaum, D. M. Bautista, G. Scherrer, and D. Julius, “Cellular and Molecular Mechanisms of Pain,” Cell 139, no. 2 (2009): 267-284.

[197] Z. Guan, J. A. Kuhn, X. Wang, et al., “Injured Sensory Neuron-derived CSF1 Induces Microglial Proliferation and DAP12-dependent Pain,” Nature Neuroscience 19, no. 1 (2016): 94-101.

[198] X. Yu, H. Liu, K. A. Hamel, et al., “Dorsal Root Ganglion Macrophages Contribute to both the Initiation and Persistence of Neuropathic Pain,” Nature Communications 11, no. 1 (2020): 264.

[199] H. Zhang, Y. Li, M. de Carvalho-Barbosa, et al., “Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy,” The Journal of Pain 17, no. 7 (2016): 775-786.

[200] N. Shinotsuka and F. Denk, “Fibroblasts: The Neglected Cell Type in Peripheral Sensitisation and Chronic Pain? A Review Based on a Systematic Search of the Literature,” BMJ Open Sci 6, no. 1 (2022): e100235.

[201] S. Davidson, M. Coles, T. Thomas, et al., “Fibroblasts as Immune Regulators in Infection, Inflammation and Cancer,” Nature Reviews Immunology 21, no. 11 (2021): 704-717.

[202] P. Singhmar, R. T. P. Trinh, J. Ma, et al., “The Fibroblast-derived Protein PI16 Controls Neuropathic Pain,” PNAS 117, no. 10 (2020): 5463-5471.

[203] H. Luo, H. Z. Liu, W. W. Zhang, et al., “Interleukin-17 Regulates Neuron-Glial Communications, Synaptic Transmission, and Neuropathic Pain After Chemotherapy,” Cell reports 29, no. 8 (2019): 2384-2397. e2385.

[204] M. Calvo, J. M. Dawes, and D. L. H. Bennett, “The Role of the Immune System in the Generation of Neuropathic Pain,” The Lancet Neurology 11, no. 7 (2012): 629-642.

[205] K. B.F. Møllgård, P. Kusk, L. M. Miyakoshi, et al., “A Mesothelium Divides the Subarachnoid Space Into Functional Compartments,” Science 379, no. 6627 (2023): 84-88.

[206] K. Alves de Lima, J. Rustenhoven, and J. Kipnis, “Meningeal Immunity and Its Function in Maintenance of the Central Nervous System in Health and Disease,” Annual Review of Immunology 38 (2020): 597-620.

[207] J. Wei, H. Liu, F. Zhou, X. Lu, H. Zhang, and L. Zhang, “The Recent Research Progress in Neurobiological Characteristics and Pain Regulation of the Cerebrospinal Fluid-contacting Nucleus,” Anesthesiology and Perioperative Science 2, no. 2 (2024).

[208] J.A. V.I. Kuhn, J. Braz, K. Hamel, et al., “Regulatory T-cells Inhibit Microglia-induced Pain Hypersensitivity in Female Mice,” Elife (2021): e69056.

[209] J. Lassen, K. H. Sturner, J. Gierthmuhlen, et al., “Protective Role of Natural Killer Cells in Neuropathic Pain Conditions,” Pain 162, no. 9 (2021): 2366-2375.

[210] Y. Li, X. He, R. Kawaguchi, et al., “Microglia-organized Scar-free Spinal Cord Repair in Neonatal Mice,” Nature 587, no. 7835 (2020): 613-618.

[211] J. Wang, X. He, H. Meng, et al., “Robust Myelination of Regenerated Axons Induced by Combined Manipulations of GPR17 and Microglia,” Neuron 108, no. 5 (2020): 876-886. e874.

[212] Y. Liu, L. J. Zhou, J. Wang, et al., “TNF-alpha Differentially Regulates Synaptic Plasticity in the Hippocampus and Spinal Cord by Microglia-Dependent Mechanisms After Peripheral Nerve Injury,” Journal of Neuroscience 37, no. 4 (2017): 871-881.

[213] L. Huang, J. Jin, and K. Chen, “BDNF Produced by Cerebral Microglia Promotes Cortical Plasticity and Pain Hypersensitivity After Peripheral Nerve Injury,” Plos Biology 19, no. 7 (2021): e3001337.

[214] N. Yousefpour, S. Locke, H. Deamond, et al., “Time-dependent and Selective Microglia-mediated Removal of Spinal Synapses in Neuropathic Pain,” Cell reports 42, no. 1 (2023): 112010.

[215] S. Tansley, N. Gu, A. U. Guzmán, et al., “Microglia-mediated Degradation of Perineuronal Nets Promotes Pain,” Neuroscience 377 (2022): 80-86.

[216] R.-R. Ji, T. Berta, and M. Nedergaard, “Glia and Pain: Is Chronic Pain a Gliopathy?,” Pain 154 (2013): S10-S28.

[217] G. Chen, C. K. Park, R. G. Xie, T. Berta, M. Nedergaard, and R. R. Ji, “Connexin-43 Induces Chemokine Release From Spinal Cord Astrocytes to Maintain Late-phase Neuropathic Pain in Mice,” Brain 137 (2014): 2193-2209. Pt 8.

[218] H. J. Lu and Y. J. Gao, “Astrocytes in Chronic Pain: Cellular and Molecular Mechanisms,” Neurosci Bull 39, no. 3 (2023): 425-439.

[219] B. C. Jiang, D. L. Cao, X. Zhang, et al., “CXCL13 drives Spinal Astrocyte Activation and Neuropathic Pain via CXCR5,” Journal of Clinical Investigation 126, no. 2 (2016): 745-761.

[220] D. S. Kim, K. W. Li, A. Boroujerdi, et al., “Thrombospondin-4 Contributes to Spinal Sensitization and Neuropathic Pain States,” Journal of Neuroscience 32, no. 26 (2012): 8977-8987.

[221] S. K. Kim, H. Hayashi, T. Ishikawa, et al., “Cortical Astrocytes Rewire Somatosensory Cortical Circuits for Peripheral Neuropathic Pain,” Journal of Clinical Investigation 126, no. 5 (2016): 1983-1997.

[222] S. Squillace, S. Spiegel, and D. Salvemini, “Targeting the Sphingosine-1-Phosphate Axis for Developing Non-narcotic Pain Therapeutics,” Trends in Pharmacological Sciences 41, no. 11 (2020): 851-867.

[223] A. C. Zarpelon, F. C. Rodrigues, A. H. Lopes, et al., “Spinal Cord Oligodendrocyte-derived Alarmin IL-33 Mediates Neuropathic Pain,” Faseb Journal 30, no. 1 (2016): 54-65.

[224] S. Gritsch, J. Lu, S. Thilemann, et al., “Oligodendrocyte Ablation Triggers central Pain Independently of Innate or Adaptive Immune Responses in Mice,” Nature Communications 5 (2014): 5472.

[225] G. Petho, B. Kantas, A. Horvath, and E. Pinter, “The Epigenetics of Neuropathic Pain: A Systematic Update,” International Journal of Molecular Sciences 24, no. 24 (2023): 17143.

[226] X. He, H. Yang, Y. Zheng, X. Zhao, and T. Wang, “The Role of Non-coding RNAs in Neuropathic Pain,” Pflugers Archiv: European journal of physiology 476, no. 11 (2024): 1625-1643.

[227] J. Garriga, G. Laumet, S. R. Chen, et al., “Nerve Injury-Induced Chronic Pain Is Associated With Persistent DNA Methylation Reprogramming in Dorsal Root Ganglion,” Journal of Neuroscience 38, no. 27 (2018): 6090-6101.

[228] D. Rodrigues, C. Monteiro, H. Cardoso-Cruz, and V. Galhardo, “Altered Brain Expression of DNA Methylation and Hydroxymethylation Epigenetic Enzymes in a Rat Model of Neuropathic Pain,” International Journal of Molecular Sciences 24, no. 8 (2023): 7305.

[229] Y. T. Zhao, J. Deng, H. M. Liu, et al., “Adaptation of Prelimbic Cortex Mediated by IL-6/STAT3/Acp5 Pathway Contributes to the Comorbidity of Neuropathic Pain and Depression in Rats,” Journal of Neuroinflammation 19, no. 1 (2022): 144.

[230] H. H. Ding, S. B. Zhang, Y. Y. Lv, et al., “TNF-α/STAT3 Pathway Epigenetically Upregulates Nav1.6 Expression in DRG and Contributes to Neuropathic Pain Induced by L5-VRT,” Journal of Neuroinflammation 16, no. 1 (2019): 29.

[231] J. Miao, Z. Chen, Y. Wu, Q. Hu, and T. Ji, “Sp1 Inhibits PGC-1α via HDAC2-Catalyzed Histone Deacetylation in Chronic Constriction Injury-Induced Neuropathic Pain,” Acs Chemical Neuroscience 13, no. 23 (2022): 3438-3452.

[232] T. B. Lin, M. C. Hsieh, C. Y. Lai, et al., “Melatonin Relieves Neuropathic Allodynia Through Spinal MT2-enhanced PP2Ac and Downstream HDAC4 Shuttling-dependent Epigenetic Modification of hmgb1 Transcription,” Journal of Pineal Research 60, no. 3 (2016): 263-276.

[233] P. Gu, T. Fan, S. S. C. Wong, et al., “Central Endothelin-1 Confers Analgesia by Triggering Spinal Neuronal Histone Deacetylase 5 (HDAC5) Nuclear Exclusion in Peripheral Neuropathic Pain in Mice,” The Journal of Pain 22, no. 4 (2021): 454-471.

[234] T. Fan, Y. Yu, Y. L. Chen, et al., “Histone Deacetylase 5-induced Deficiency of Signal Transducer and Activator of Transcription-3 Acetylation Contributes to Spinal Astrocytes Degeneration in Painful Diabetic Neuropathy,” Glia 71, no. 4 (2023): 1099-1119.

[235] S. H. Chen, Y. W. Lin, W. L. Tseng, W. T. Lin, S. C. Lin, and Y. Y. Hsueh, “Ultrahigh Frequency Transcutaneous Electrical Nerve Stimulation for Neuropathic Pain Alleviation and Neuromodulation,” Neurotherapeutics 21, no. 3 (2024): e00336.

[236] R. Yadav and H. R. Weng, “EZH2 regulates Spinal Neuroinflammation in Rats With Neuropathic Pain,” Neuroscience 349 (2017): 106-117.

[237] Q. An, C. Sun, R. Li, et al., “Calcitonin Gene-related Peptide Regulates Spinal Microglial Activation Through the Histone H3 Lysine 27 Trimethylation via Enhancer of Zeste Homolog-2 in Rats With Neuropathic Pain,” Journal of Neuroinflammation 18, no. 1 (2021): 117.

[238] J. He, H. B. Wang, J. J. Huang, et al., “Diabetic Neuropathic Pain Induced by Streptozotocin Alters the Expression Profile of Non-coding RNAs in the Spinal Cord of Mice as Determined by Sequencing Analysis,” Exp Ther Med 22, no. 1 (2021): 775.

[239] J. Zhou, Q. Xiong, H. Chen, C. Yang, and Y. Fan, “Identification of the Spinal Expression Profile of Non-coding RNAs Involved in Neuropathic Pain Following Spared Nerve Injury by Sequence Analysis,” Front Mol Neurosci 10 (2017): 91.

[240] M. Li, F. Zhou, and Y. Tian, “The Role of microRNAs in Anesthesia and Pain: Insights From the 2024 Nobel Prize in Physiology or Medicine,” Anesthesiology and Perioperative Science 3, no. 3 (2025): 31.

[241] S. Tripathi, B. Shree, S. Mohapatra, A. Swati Basu, and V. Sharma, “The Expanding Regulatory Mechanisms and Cellular Functions of Long Non-coding RNAs (lncRNAs) in Neuroinflammation,” Molecular Neurobiology 58, no. 6 (2021): 2916-2939.

[242] C. Zhang, H. Sha, Y. Peng, Y. Wang, C. Liu, and X. Zhou, “PiRNA-DQ541777 Contributes to Neuropathic Pain via Targeting Cdk5rap1,” Journal of Neuroscience 39, no. 45 (2019): 9028-9039.

[243] H. S. Kim, D. Lee, and S. Shen, “Endoplasmic Reticular Stress as an Emerging Therapeutic Target for Chronic Pain: A Narrative Review,” British Journal of Anaesthesia 132, no. 4 (2024): 707-724.

[244] B. Inceoglu, A. Bettaieb, C. A. Trindade da Silva, K. S. Lee, F. G. Haj, and B. D. Hammock, “Endoplasmic Reticulum Stress in the Peripheral Nervous System Is a Significant Driver of Neuropathic Pain,” PNAS 112, no. 29 (2015): 9082-9087.

[245] S. Lupachyk, P. Watcho, A. A. Obrosov, R. Stavniichuk, and I. G. Obrosova, “Endoplasmic Reticulum Stress Contributes to Prediabetic Peripheral Neuropathy,” Experimental Neurology 247 (2013): 342-348.

[246] E. J. Rodriguez-Palma, S. Huerta de la Cruz, A. M. Islas-Espinoza, G. Castaneda-Corral, V. Granados-Soto, and R. Khanna, “Nociplastic Pain Mechanisms and Toll-Like Receptors as Promising Targets for Its Management,” Pain 165, no. 10 (2024): 2150-2164.

[247] I. Mawla, Z. Huang, C. M. Kaplan, et al., “Large-scale Momentary Brain co-activation Patterns Are Associated With Hyperalgesia and Mediate Focal Neurochemistry and Cross-network Functional Connectivity in Fibromyalgia,” Pain 164, no. 12 (2023): 2737-2748.

[248] A. A. Atta, W. W. Ibrahim, A. F. Mohamed, and N. F. Abdelkader, “Microglia Polarization in Nociplastic Pain: Mechanisms and Perspectives,” Inflammopharmacology 31, no. 3 (2023): 1053-1067.

[249] T. L. Pyke, P. G. Osmotherly, and S. Baines, “Measuring Glutamate Levels in the Brains of Fibromyalgia Patients and a Potential Role for Glutamate in the Pathophysiology of Fibromyalgia Symptoms: A Systematic Review,” Clinical Journal of Pain 33, no. 10 (2017): 944-954.

[250] J. Lee, O. C. Andronesi, A. Torrado-Carvajal, et al., “3D magnetic Resonance Spectroscopic Imaging Reveals Links Between Brain Metabolites and Multidimensional Pain Features in Fibromyalgia,” European Journal of Pain (London, England) 25, no. 9 (2021): 2050-2064.

[251] A. L. Peek, T. Rebbeck, N. A. Puts, J. Watson, M. R. Aguila, and A. M. Leaver, “Brain GABA and Glutamate Levels Across Pain Conditions: A Systematic Literature Review and Meta-analysis of 1H-MRS Studies Using the MRS-Q Quality Assessment Tool,” Neuroimage 210 (2020): 116532.

[252] S. P. Cohen, M. H. Verdolin, A. S. Chang, C. Kurihara, B. J. Morlando, and J. Mao, “The Intravenous Ketamine Test Predicts Subsequent Response to an Oral Dextromethorphan Treatment Regimen in Fibromyalgia Patients,” The Journal of Pain 7, no. 6 (2006): 391-398.

[253] T. Graven-Nielsen, S. A. Kendall, K. G. Henriksson, et al., “Ketamine Reduces Muscle Pain, Temporal Summation, and Referred Pain in Fibromyalgia Patients,” Pain 85, no. 3 (2000): 483-491.

[254] A. Kaur, L. Singh, N. Singh, M. S. Bhatti, and R. Bhatti, “Ameliorative Effect of imperatorin in Chemically Induced Fibromyalgia: Role of NMDA/NFkB Mediated Downstream Signaling,” Biochemical Pharmacology 166 (2019): 56-69.

[255] S. Li, J. Han, D. S. Wang, et al., “Echinocystic Acid Reduces Reserpine-induced Pain/Depression Dyad in Mice,” Metabolic Brain Disease 31, no. 2 (2016): 455-463.

[256] B. R. Foerster, M. Petrou, R. A. Edden, et al., “Reduced Insular γ-aminobutyric Acid in Fibromyalgia,” Arthritis and Rheumatism 64, no. 2 (2012): 579-583.

[257] Y. E. De la Luz-Cuellar, E. J. Rodríguez-Palma, Ú. Franco-Enzástiga, et al., “Blockade of Spinal α(5)-GABA(A) Receptors Differentially Reduces Reserpine-induced Fibromyalgia-type Pain in Female Rats,” European Journal of Pharmacology 858 (2019): 172443.

[258] I. J. Russell, H. Vaeroy, M. Javors, and F. Nyberg, “Cerebrospinal Fluid Biogenic Amine Metabolites in Fibromyalgia/Fibrositis Syndrome and Rheumatoid Arthritis,” Arthritis and Rheumatism 35, no. 5 (1992): 550-556.

[259] J. N. Baraniuk, G. Whalen, J. Cunningham, and D. J. Clauw, “Cerebrospinal Fluid Levels of Opioid Peptides in Fibromyalgia and Chronic Low Back Pain,” BMC Musculoskeletal Disorders 5 (2004): 48.

[260] R. E. Harris, D. J. Clauw, D. J. Scott, S. A. McLean, R. H. Gracely, and J. K. Zubieta, “Decreased central Mu-opioid Receptor Availability in Fibromyalgia,” Journal of Neuroscience 27, no. 37 (2007): 10000-10006.

[261] D. Clauw, “Hijacking the Endogenous Opioid System to Treat Pain: Who Thought It Would be so Complicated?,” Pain 158, no. 12 (2017): 2283-2284.

[262] D. K. Patten, B. G. Schultz, and D. J. Berlau, “The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders,” Pharmacotherapy 38, no. 3 (2018): 382-389.

[263] Y. Nagakura, T. Oe, T. Aoki, and N. Matsuoka, “Biogenic Amine Depletion Causes Chronic Muscular Pain and Tactile Allodynia Accompanied by Depression: A Putative Animal Model of Fibromyalgia,” Pain 146, no. 1-2 (2009): 26-33.

[264] N. Murai, H. Fushiki, S. Honda, et al., “Relationship Between Serotonin Transporter Occupancies and Analgesic Effects of AS1069562, the (+)-isomer of Indeloxazine, and Duloxetine in Reserpine-induced Myalgia Rats,” Neuroscience 289 (2015): 262-269.

[265] S. Ogino, Y. Nagakura, M. Tsukamoto, et al., “Systemic Administration of 5-HT(2C) Receptor Agonists Attenuates Muscular Hyperalgesia in Reserpine-induced Myalgia Model,” Pharmacology Biochemistry and Behavior 108 (2013): 8-15.

[266] M. Haack, N. Simpson, N. Sethna, S. Kaur, and J. Mullington, “Sleep Deficiency and Chronic Pain: Potential Underlying Mechanisms and Clinical Implications,” Neuropsychopharmacology 45, no. 1 (2020): 205-216.

[267] S. Sha, H. Liu, and H. Zhang, “Neural Circuits for Active Resilience to Empathic Pain,” Anesthesiology and Perioperative Science 2, no. 4 (2024): 36.

[268] K. C. Light, E. E. Bragdon, K. M. Grewen, K. A. Brownley, S. S. Girdler, and W. Maixner, “Adrenergic Dysregulation and Pain With and Without Acute Beta-blockade in Women With Fibromyalgia and Temporomandibular Disorder,” The Journal of Pain 10, no. 5 (2009): 542-552.

[269] E. Legangneux, J. J. Mora, O. Spreux-Varoquaux, et al., “Cerebrospinal Fluid Biogenic Amine Metabolites, Plasma-rich Platelet Serotonin and [3H]Imipramine Reuptake in the Primary Fibromyalgia Syndrome,” Rheumatology 40, no. 3 (2001): 290-296.

[270] T. T. Zhang, R. Xue, L. Zhu, et al., “Evaluation of the Analgesic Effects of Ammoxetine, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor,” Acta Pharmacologica Sinica 37, no. 9 (2016): 1154-1165.

[271] R. Lewis-Fernández, P. Lam, S. Lucak, et al., “An Open-Label Pilot Study of Duloxetine in Patients with Irritable Bowel Syndrome and Comorbid Major Depressive Disorder,” Journal of Clinical Psychopharmacology 36, no. 6 (2016): 710-715.

[272] P. B. Wood, P. Schweinhardt, E. Jaeger, et al., “Fibromyalgia Patients Show an Abnormal Dopamine Response to Pain,” European Journal of Neuroscience 25, no. 12 (2007): 3576-3582.

[273] I. K. Martikainen, E. B. Nuechterlein, M. Peciña, et al., “Chronic Back Pain Is Associated With Alterations in Dopamine Neurotransmission in the Ventral Striatum,” Journal of Neuroscience 35, no. 27 (2015): 9957-9965.

[274] P. B. Wood and A. J. Holman, “An Elephant Among Us: The Role of Dopamine in the Pathophysiology of Fibromyalgia,” The Journal of Rheumatology 36, no. 2 (2009): 221-224.

[275] Y. E. De la Luz-Cuellar, E. J. Rodríguez-Palma, Ú. Franco-Enzástiga, M. Déciga-Campos, F. Mercado, and V. Granados-Soto, “Spinal Dopaminergic D(1) and D(5) Receptors Contribute to Reserpine-induced Fibromyalgia-Like Pain in Rats,” Brain Research 1799 (2023): 148167.

[276] C. P. Martins, R. S. Paes, G. M. Baldasso, et al., “Pramipexole, a Dopamine D3/D2 Receptor-preferring Agonist, Attenuates Reserpine-induced Fibromyalgia-Like Model in Mice,” Neural Regen Res 17, no. 2 (2022): 450-458.

[277] W. Zhang, X. Zhang, M. Lei, et al., “Dopamine D2 Receptor Activation Blocks GluA2/ROS Positive Feedback Loop to Alienate Chronic-Migraine-Associated Pain Sensitization,” Antioxidants (Basel) 13, no. 6 (2024): 725.

[278] C. A. Bouchet and S. L. Ingram, “Cannabinoids in the Descending Pain Modulatory Circuit: Role in Inflammation,” Pharmacology & Therapeutics 209 (2020): 107495.

[279] S. P. Ang, S. Sidharthan, W. Lai, et al., “Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks,” Pain Ther 12, no. 2 (2023): 355-375.

[280] K. Starowicz and D. P. Finn, “Cannabinoids and Pain: Sites and Mechanisms of Action,” Advances in Pharmacology (San Diego, Calif) 80 (2017): 437-475.

[281] P. Sarchielli, L. A. Pini, F. Coppola, et al., “Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure,” Neuropsychopharmacology 32, no. 6 (2007): 1384-1390.

[282] S. L. Bourke, A. K. Schlag, S. E. O'Sullivan, D. J. Nutt, and D. P. Finn, “Cannabinoids and the Endocannabinoid System in Fibromyalgia: A Review of Preclinical and Clinical Research,” Pharmacology & Therapeutics 240 (2022): 108216.

[283] L. Singh, A. Kaur, S. Garg, A. P. Singh and, R. Bhatti, “Protective Effect of Esculetin, Natural Coumarin in Mice Model of Fibromyalgia: Targeting Pro-Inflammatory Cytokines and MAO-A,” Neurochemical Research 45, no. 10 (2020): 2364-2374.

[284] B. C. Sutton and M. R. Opp, “Acute Increases in Intramuscular Inflammatory Cytokines Are Necessary for the Development of Mechanical Hypersensitivity in a Mouse Model of Musculoskeletal Sensitization,” Brain, Behavior, and Immunity 44 (2015): 213-220.

[285] A. Leung, N. S. Gregory, L. H. Allen, and K. A. Sluka, “Regular Physical Activity Prevents Chronic Pain by Altering Resident Muscle Macrophage Phenotype and Increasing Interleukin-10 in Mice,” Pain 157, no. 1 (2016): 70-79.

[286] D. Kadetoff, J. Lampa, M. Westman, M. Andersson, and E. Kosek, “Evidence of central Inflammation in Fibromyalgia-increased Cerebrospinal Fluid Interleukin-8 Levels,” Journal of Neuroimmunology 242, no. 1-2 (2012): 33-38.

[287] E. Bäckryd, L. Tanum, A. L. Lind, A. Larsson, and T. Gordh, “Evidence of both Systemic Inflammation and Neuroinflammation in Fibromyalgia Patients, as Assessed by a Multiplex Protein Panel Applied to the Cerebrospinal Fluid and to Plasma,” J Pain Res 10 (2017): 515-525.

[288] C. Mueller, I. Jordan, C. Jones, P. Lawson, and J. W. Younger, “Abnormal Immune System Response in the Brain of Women With Fibromyalgia After Experimental Endotoxin Challenge,” Brain Behav Immun Health 30 (2023): 100624.

[289] D. S. Albrecht, A. Forsberg, A. Sandstrom, et al., “Brain Glial Activation in Fibromyalgia—A Multi-site Positron Emission Tomography Investigation,” Brain, Behavior, and Immunity 75 (2019): 72-83.

[290] M. Ohgidani, T. A. Kato, M. Hosoi, et al., “Fibromyalgia and Microglial TNF-α: Translational Research Using human Blood Induced Microglia-Like Cells,” Scientific Reports 7, no. 1 (2017): 11882.

[291] T. Stratz, B. Fiebich, U. Haus, and W. Müller, “Influence of Tropisetron on the Serum Substance P Levels in Fibromyalgia Patients,” Scandinavian Journal of Rheumatology Supplement 119 (2004): 41-43.

[292] X. Liu, W. Yang, C. Zhu, et al., “Toll-Like Receptors and Their Role in Neuropathic Pain and Migraine,” Mol Brain 15, no. 1 (2022): 73.

[293] M. J. Lacagnina, L. R. Watkins, and P. M. Grace, “Toll-Like Receptors and Their Role in Persistent Pain,” Pharmacology & Therapeutics 184 (2018): 145-158.

[294] C. K. Park, Z. Z. Xu, T. Berta, et al., “Extracellular microRNAs Activate Nociceptor Neurons to Elicit Pain via TLR7 and TRPA1,” Neuron 82, no. 1 (2014): 47-54.

[295] A. Schrepf, C. S. Bradley, and M. O'Donnell, “Toll-Like Receptor 4 and Comorbid Pain in Interstitial Cystitis/Bladder Pain Syndrome: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Study,” Brain, Behavior, and Immunity 49 (2015): 66-74.

[296] A. Schrepf, C. Kaplan, R. E. Harris, et al., “Stimulated Whole-blood Cytokine/Chemokine Responses Are Associated With Interstitial Cystitis/Bladder Pain Syndrome Phenotypes and Features of Nociplastic Pain: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Study,” Pain 164, no. 5 (2023): 1148-1157.

[297] I. M. Marone, F. De Logu, R. Nassini, et al., “TRPA1/NOX in the Soma of Trigeminal Ganglion Neurons Mediates Migraine-related Pain of Glyceryl Trinitrate in Mice,” Brain 141, no. 8 (2018): 2312-2328.

[298] L. Edvinsson, “CGRP Receptor Antagonists and Antibodies Against CGRP and Its Receptor in Migraine Treatment,” British Journal of Clinical Pharmacology 80, no. 2 (2015): 193-199.

[299] A. Goebel, E. Krock, C. Gentry, et al., “Passive Transfer of Fibromyalgia Symptoms From Patients to Mice,” Journal of Clinical Investigation 131, no. 13 (2021): e144201.

[300] S. B.S. Caxaria, A. M. Fuller, R. Evans, et al., “Neutrophils Infiltrate Sensory Ganglia and Mediate Chronic Widespread Pain in Fibromyalgia,” Proceedings of the National Academy of Sciences 120, no. 17 (2023): e2211631120.

[301] E. Krock, C. E. Morado-Urbina, J. Menezes, et al., “Fibromyalgia Patients With Elevated Levels of Anti-satellite Glia Cell Immunoglobulin G Antibodies Present With More Severe Symptoms,” Pain 164, no. 8 (2023): 1828-1840.

[302] Y. Wei, Y. Liang, H. Lin, Y. Dai, and S. Yao, “Autonomic Nervous System and Inflammation Interaction in Endometriosis-associated Pain,” Journal of Neuroinflammation 17, no. 1 (2020): 80.

[303] R. Freynhagen, R. Rey, and C. Argoff, “When to Consider “Mixed Pain”? The Right Questions Can Make a Difference,” Current Medical Research and Opinion 36, no. 12 (2020): 2037-2046.

[304] P. J. Ibor, I. Sánchez-Magro, J. Villoria, A. Leal, and A. Esquivias, “Mixed Pain Can Be Discerned in the Primary Care and Orthopedics Settings in Spain: A Large Cross-Sectional Study,” Clinical Journal of Pain 33, no. 12 (2017): 1100-1108.

[305] S. U. Ahmed, Y. Zhang, L. Chen, et al., “Effect of 1.5% Topical Diclofenac on Clinical Neuropathic Pain,” Anesthesiology 123, no. 1 (2015): 191-198.

[306] M. Fernandez-Fairen, C. A. Calderon-Ospina, J. Chen, et al., “A Latin American Consensus Meeting on the Essentials of Mixed Pain,” Current Medical Research and Opinion 39, no. 3 (2023): 451-466.

[307] S. L. Kolasinski, T. Neogi, M. C. Hochberg, et al., “American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee,” Arthritis Care Res (Hoboken) 72, no. 2 (2020): 149-162.

[308] R. J. Gatchel, D. D. McGeary, C. A. McGeary, and B. Lippe, “Interdisciplinary Chronic Pain Management: Past, Present, and Future,” The American Psychologist 69, no. 2 (2014): 119-130.

[309] J. Steglitz, J. Buscemi, and M. J. Ferguson, “The Future of Pain Research, Education, and Treatment: A Summary of the IOM Report “Relieving Pain in America”: A Blueprint for Transforming Prevention, Care, Education, and Research,” Translational Behavioral Medicine 2, no. 1 (2012): 6-8.

[310] A. A. Khan, M. Iadarola, H. Y. Yang, and R. A. Dionne, “Expression of COX-1 and COX-2 in a Clinical Model of Acute Inflammation,” The Journal of Pain 8, no. 4 (2007): 349-354.

[311] I. A. Khasabova, M. Uhelski, S. G. Khasabov, K. Gupta, V. S. Seybold, and D. A. Simone, “Sensitization of Nociceptors by Prostaglandin E(2)-glycerol Contributes to Hyperalgesia in Mice With Sickle Cell Disease,” Blood 133, no. 18 (2019): 1989-1998.

[312] A. Preisner, S. Albrecht, Q. L. Cui, et al., “Non-steroidal Anti-inflammatory Drug Indometacin Enhances Endogenous Remyelination,” Acta Neuropathologica 130, no. 2 (2015): 247-261.

[313] N. Aldamluji, A. Burgess, E. Pogatzki-Zahn, J. Raeder, and H. Beloeil, “PROSPECT Guideline for Tonsillectomy: Systematic Review and Procedure-specific Postoperative Pain Management Recommendations,” Anaesthesia 76, no. 7 (2021): 947-961.

[314] A. Qaseem, R. P. Harris, M. A. Forciea, et al., “Management of Acute and Recurrent Gout: A Clinical Practice Guideline from the American College of Physicians,” Annals of Internal Medicine 166, no. 1 (2017): 58-68.

[315] N. K. Arden, T. A. Perry, R. R. Bannuru, et al., “Non-surgical Management of Knee Osteoarthritis: Comparison of ESCEO and OARSI 2019 Guidelines,” Nat Rev Rheumatol 17, no. 1 (2021): 59-66.

[316] C. Mallet, J. Desmeules, R. Pegahi, and A. Eschalier, “An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact,” J Pain Res 16 (2023): 1081-1094.

[317] S. Perrot, A. Eschalier, J. Desmeules, M. Lanteri-Minet, and N. Attal, “Practice Guidelines for the Treatment of Acute Migraine and Chronic Knee Osteoarthritis With Paracetamol: An Expert Appraisal on Evolution Over Time Between Scientific Societies,” Current Medical Research and Opinion 38, no. 9 (2022): 1579-1585.

[318] P. Richette, M. Doherty, E. Pascual, et al., “2016 updated EULAR Evidence-based Recommendations for the Management of gout,” Annals of the Rheumatic Diseases 76, no. 1 (2017): 29-42.

[319] I. Yalcin, N. Choucair-Jaafar, M. Benbouzid, et al., “beta(2)-adrenoceptors Are Critical for Antidepressant Treatment of Neuropathic Pain,” Annals of Neurology 65, no. 2 (2009): 218-225.

[320] J. Bernatoniene, A. Sciupokas, D. M. Kopustinskiene, and K. Petrikonis, “Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain,” Pharmaceutics 15, no. 7 (2023).

[321] Y. H. Tai, Y. H. Wang, J. J. Wang, P. L. Tao, C. S. Tung, and C. S. Wong, “Amitriptyline Suppresses Neuroinflammation and Up-regulates Glutamate Transporters in Morphine-tolerant Rats,” Pain 124, no. 1-2 (2006): 77-86.

[322] S. H. Sindrup, M. Otto, N. B. Finnerup, and T. S. Jensen, “Antidepressants in the Treatment of Neuropathic Pain,” Basic & Clinical Pharmacology & Toxicology 96, no. 6 (2005): 399-409.

[323] Y. C. Lee and P. P. Chen, “A Review of SSRIs and SNRIs in Neuropathic Pain,” Expert Opinion on Pharmacotherapy 11, no. 17 (2010): 2813-2825.

[324] A. Faisco, R. Dinis, T. Seixas, and L. Lopes, “Ketamine in Chronic Pain: A Review,” Cureus 16, no. 2 (2024): e53365.

[325] F. Guirimand, X. Dupont, L. Brasseur, M. Chauvin, and D. Bouhassira, “The Effects of Ketamine on the Temporal Summation (wind-up) of the R(III) Nociceptive Flexion Reflex and Pain in Humans,” Anesthesia and Analgesia 90, no. 2 (2000): 408-414.

[326] A. R. Liu, Z. J. Lin, M. Wei, et al., “The Potent Analgesia of Intrathecal 2R, 6R-HNK via TRPA1 Inhibition in LF-PENS-induced Chronic Primary Pain Model,” J Headache Pain 24, no. 1 (2023): 141.

[327] J. E. Israel, S. St Pierre, E. Ellis, et al., “Ketamine for the Treatment of Chronic Pain: A Comprehensive Review,” Health Psychol Res 9, no. 1 (2021): 25535.

[328] B. S. Lee, I. G. Jun, S. H. Kim, and J. Y. Park, “Intrathecal Gabapentin Increases Interleukin-10 Expression and Inhibits Pro-inflammatory Cytokine in a Rat Model of Neuropathic Pain,” Journal of Korean Medical Science 28, no. 2 (2013): 308-314.

[329] N. Attal, G. Cruccu, R. Baron, et al., “EFNS Guidelines on the Pharmacological Treatment of Neuropathic Pain: 2010 Revision,” European Journal of Neurology 17, no. 9 (2010): 1113-e1188.

[330] N. B. Finnerup, N. Attal, S. Haroutounian, et al., “Pharmacotherapy for Neuropathic Pain in Adults: A Systematic Review and Meta-analysis,” Lancet Neurology 14, no. 2 (2015): 162-173.

[331] C. P. Hannon, Y. A. Fillingham, J. A. Browne, et al., “Gabapentinoids in Total Joint Arthroplasty: The Clinical Practice Guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society,” The Journal of Arthroplasty 35, no. 10 (2020): 2700-2703.

[332] M. Voute, V. Morel, and G. Pickering, “Topical Lidocaine for Chronic Pain Treatment,” Drug Des Devel Ther 15 (2021): 4091-4103.

[333] H. Hermanns, M. W. Hollmann, M. F. Stevens, et al., “Molecular Mechanisms of Action of Systemic Lidocaine in Acute and Chronic Pain: A Narrative Review,” British Journal of Anaesthesia 123, no. 3 (2019): 335-349.

[334] M. R. Ghovanloo, M. Estacion, G. P. Higerd-Rusli, P. Zhao, S. Dib-Hajj, and S. G. Waxman, “Inhibition of Sodium Conductance by Cannabigerol Contributes to a Reduction of Dorsal Root Ganglion Neuron Excitability,” British Journal of Pharmacology 179, no. 15 (2022): 4010-4030.

[335] H. Tran, Y. Feng, D. Chao, L. Q-s, Q. H. Hogan, and B. Pan, “Descending Mechanism by Which Medial Prefrontal Cortex Endocannabinoid Signaling Controls the Development of Neuropathic Pain and Neuronal Activity of Dorsal Root Ganglion,” Pain 165, no. 1 (2024): 102-114.

[336] L. Basso, R. Aboushousha, C. Y. Fan, et al., “TRPV1 promotes Opioid Analgesia During Inflammation,” Science Signaling 12, no. 575 (2019): eaav0711.

[337] F. Sandbrink, J. L. Murphy, M. Johansson, et al., “The Use of Opioids in the Management of Chronic Pain: Synopsis of the 2022 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline,” Annals of Internal Medicine 176, no. 3 (2023): 388-397.

[338] D. Moulin, A. Boulanger, A. J. Clark, et al., “Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement From the Canadian Pain Society,” Pain Research & Management 19, no. 6 (2014): 328-335.

[339] V. Arora, J. N. Campbell, and M. K. Chung, “Fight Fire With Fire: Neurobiology of Capsaicin-induced Analgesia for Chronic Pain,” Pharmacology & Therapeutics 220 (2021): 107743.

[340] S. Derry, A. S. Rice, P. Cole, T. Tan, and R. A. Moore, “Topical Capsaicin (high concentration) for Chronic Neuropathic Pain in Adults,” Cochrane Database of Systematic Reviews (Online) 1, no. 1 (2017): Cd007393.

[341] A. V. L. de Araújo, J. F. O. Neiva, C. B. M. Monteiro, and F. H. Magalhães, “Efficacy of Virtual Reality Rehabilitation After Spinal Cord Injury: A Systematic Review,” BioMed research international 2019 (2019): 7106951.

[342] S. Grassini, “Virtual Reality Assisted Non-Pharmacological Treatments in Chronic Pain Management: A Systematic Review and Quantitative Meta-Analysis,” International Journal of Environmental Research and Public Health 19, no. 7 (2022): 4071.

[343] M. Wu, W. Song, M. Zhang, L. Teng, Q. Tang, and L. Zhu, “Potential Mechanisms of Exercise for Relieving Inflammatory Pain: A Literature Review of Animal Studies,” Frontiers in aging neuroscience 16 (2024): 1359455.

[344] R. Zhang, L. Lao, K. Ren, and B. M. Berman, “Mechanisms of Acupuncture-electroacupuncture on Persistent Pain,” Anesthesiology 120, no. 2 (2014): 482-503.

[345] H. Knotkova, C. Hamani, E. Sivanesan, et al., “Neuromodulation for Chronic Pain,” Lancet 397, no. 10289 (2021): 2111-2124.

[346] J. P. Lefaucheur, Y. Fan, and B. Fan, “The Evolving Landscape of Neuromodulation for Pain Care,” Cell Rep Med 5, no. 10 (2024): 101787.

[347] R. Chou, R. Deyo, J. Friedly, et al., “Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline,” Annals of Internal Medicine 166, no. 7 (2017): 480-492.

[348] B. J. H. Yarborough, S. P. Stumbo, A. Stoneburner, et al., “Correlates of Benzodiazepine Use and Adverse Outcomes among Patients With Chronic Pain Prescribed Long-term Opioid Therapy,” Pain Medicine (Malden, Mass.) 20, no. 6 (2019): 1148-1155.

[349] G. Varrassi, E. Alon, M. Bagnasco, et al., “Towards an Effective and Safe Treatment of Inflammatory Pain: A Delphi-Guided Expert Consensus,” Advances in Therapy 36, no. 10 (2019): 2618-2637.

[350] P. Sarzi-Puttini, F. Atzeni, L. Lanata, and M. Bagnasco, “Efficacy of Ketoprofen vs. ibuprofen and Diclofenac: A Systematic Review of the Literature and Meta-analysis,” Clinical and Experimental Rheumatology 31, no. 5 (2013): 731-738.

[351] T. Rhen and J. A. Cidlowski, “Antiinflammatory Action of Glucocorticoids-new Mechanisms for Old Drugs,” New England Journal of Medicine 353, no. 16 (2005): 1711-1723.

[352] T. Satapathy, D. Sahu, H. Sahu, R. K. Pandey, S. S. Shukla, and B. Gidwani, “Trends on Nanomedicines as Novel Therapeutics Approach in Targeting Nociceptors for Relieving Pain,” Current Drug Targets (2024).

[353] W. Zhang, M. Doherty, T. Bardin, et al., “EULAR Evidence Based Recommendations for Gout. Part II: Management. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT),” Annals of the Rheumatic Diseases 65, no. 10 (2006): 1312-1324.

[354] R. Verma, S. Kumar, P. Garg, and Y. K. Verma, “Platelet-rich Plasma: A Comparative and Economical Therapy for Wound Healing and Tissue Regeneration,” Cell and Tissue Banking 24, no. 2 (2023): 285-306.

[355] R. Linertová, T. Del Pino-Sedeño, L. G. Pérez, et al., “Cost-effectiveness of Platelet-Rich Plasma for Diabetic Foot Ulcer in Spain,” The International Journal of Lower Extremity Wounds 20, no. 2 (2021): 119-127.

[356] A. So, T. De Smedt, S. Revaz, and J. Tschopp, “A Pilot Study of IL-1 Inhibition by anakinra in Acute Gout,” Arthritis Research & Therapy 9, no. 2 (2007): R28.

[357] R. Terkeltaub, J. S. Sundy, H. R. Schumacher, et al., “The Interleukin 1 Inhibitor rilonacept in Treatment of Chronic Gouty Arthritis: Results of a Placebo-controlled, Monosequence Crossover, Non-randomised, Single-blind Pilot Study,” Annals of the Rheumatic Diseases 68, no. 10 (2009): 1613-1617.

[358] B. Bannwarth and M. Kostine, “Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?,” Drugs 77, no. 13 (2017): 1377-1387.

[359] B. Zhang, Y. S. Roh, S. Liang, et al., “Neurotropin Suppresses Inflammatory Cytokine Expression and Cell Death Through Suppression of NF-κB and JNK in Hepatocytes,” PLoS ONE 9, no. 12 (2014): e114071.

[360] R. W. Jackman, M. G. Rhoads, E. Cornwell, and S. C. Kandarian, “Microtubule-mediated NF-kappaB Activation in the TNF-alpha Signaling Pathway,” Experimental Cell Research 315, no. 19 (2009): 3242-3249.

[361] T. Misawa, M. Takahama, T. Kozaki, et al., “Microtubule-driven Spatial Arrangement of Mitochondria Promotes Activation of the NLRP3 Inflammasome,” Nature Immunology 14, no. 5 (2013): 454-460.

[362] R. Ramonda, F. Oliviero, P. Galozzi, et al., “Molecular Mechanisms of Pain in Crystal-induced Arthritis,” Best Practice & Research Clinical Rheumatology 29, no. 1 (2015): 98-110.

[363] P. J. Wiffen, S. Derry, R. F. Bell, et al., “Gabapentin for Chronic Neuropathic Pain in Adults,” Cochrane Database of Systematic Reviews (Online) 6, no. 6 (2017): Cd007938.

[364] R. A. Moore, S. Straube, P. J. Wiffen, S. Derry, and H. J. McQuay, “Pregabalin for Acute and Chronic Pain in Adults,” Cochrane Database of Systematic Reviews (Online), no. 3 (2009): Cd007076.

[365] C. Tong, Z. Zhengyao, L. Mei, S. Dongpo, H. Qian, and M. Fengqun, “Pregabalin and Gabapentin in Patients With Spinal Cord Injury-Related Neuropathic Pain: A Network Meta-Analysis,” Pain Ther 10, no. 2 (2021): 1497-1509.

[366] M. Thouaye and I. Yalcin, “Neuropathic Pain: From Actual Pharmacological Treatments to New Therapeutic Horizons,” Pharmacology & Therapeutics 251 (2023): 108546.

[367] M. Anger, T. Valovska, H. Beloeil, et al., “PROSPECT Guideline for Total Hip Arthroplasty: A Systematic Review and Procedure-specific Postoperative Pain Management Recommendations,” Anaesthesia 76, no. 8 (2021): 1082-1097.

[368] M. Kremer, E. Salvat, A. Muller, I. Yalcin, and M. Barrot, “Antidepressants and Gabapentinoids in Neuropathic Pain: Mechanistic Insights,” Neuroscience 338 (2016): 183-206.

[369] T. Saarto and P. J. Wiffen, “Antidepressants for Neuropathic Pain,” Cochrane Database of Systematic Reviews (Online) 2007, no. 4 (2007): Cd005454.

[370] A. Ansari, “The Efficacy of Newer Antidepressants in the Treatment of Chronic Pain: A Review of Current Literature,” Harvard Review of Psychiatry 7, no. 5 (2000): 257-277.

[371] G. Di Stefano, G. De Stefano, C. Leone, et al., “Real-world Effectiveness and Tolerability of Carbamazepine and Oxcarbazepine in 354 Patients With Trigeminal Neuralgia,” European Journal of Pain (London, England) 25, no. 5 (2021): 1064-1071.

[372] E. Gambeta, J. G. Chichorro, and G. W. Zamponi, “Trigeminal Neuralgia: An Overview From Pathophysiology to Pharmacological Treatments,” Mol Pain 16 (2020): 1744806920901890.

[373] J. Park and H. J. Park, “Botulinum Toxin for the Treatment of Neuropathic Pain,” Toxins (Basel) 9, no. 9 (2017): 260.

[374] H. P. Hartung, R. Mallick, V. Bril, et al., “Patient-reported Outcomes With Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: The PATH Study,” European Journal of Neurology 27, no. 1 (2020): 196-203.

[375] Y. H. Huang, H. C. Chen, K. W. Huang, et al., “Intravenous Immunoglobulin for Postpolio Syndrome: A Systematic Review and Meta-analysis,” BMC Neurology 15 (2015): 39.

[376] A. M. Durán, L. M. Salto, J. Câmara, et al., “Effects of Omega-3 Polyunsaturated Fatty-acid Supplementation on Neuropathic Pain Symptoms and Sphingosine Levels in Mexican-Americans With Type 2 Diabetes,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 12 (2019): 109-120.

[377] A. M. Durán, W. L. Beeson, A. Firek, Z. Cordero-MacIntyre, and M. De León, “Dietary Omega-3 Polyunsaturated Fatty-Acid Supplementation Upregulates Protective Cellular Pathways in Patients With Type 2 Diabetes Exhibiting Improvement in Painful Diabetic Neuropathy,” Nutrients 14, no. 4 (2022): 761.

[378] G. D. Ko, N. B. Nowacki, L. Arseneau, M. Eitel, and A. Hum, “Omega-3 Fatty Acids for Neuropathic Pain: Case Series,” The Clinical Journal of Pain 26, no. 2 (2010): 168-172.

[379] S. P. Cohen, N. Bogduk, A. Dragovich, et al., “Randomized, Double-blind, Placebo-controlled, Dose-response, and Preclinical Safety Study of Transforaminal Epidural Etanercept for the Treatment of Sciatica,” Anesthesiology 110, no. 5 (2009): 1116-1126.

[380] S. Ohtori, M. Miyagi, Y. Eguchi, et al., “Efficacy of Epidural Administration of Anti-interleukin-6 Receptor Antibody Onto Spinal Nerve for Treatment of Sciatica,” European Spine Journal 21, no. 10 (2012): 2079-2084.

[381] J. Karppinen, T. Korhonen, A. Malmivaara, et al., “Tumor Necrosis Factor-alpha Monoclonal Antibody, infliximab, Used to Manage Severe Sciatica,” Spine (Phila Pa 1976) 28, no. 8 (2003): 750-753. discussion 753-754.

[382] N. H. Williams, R. Lewis, N. U. Din, et al., “A Systematic Review and Meta-analysis of Biological Treatments Targeting Tumour Necrosis Factor α for Sciatica,” European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 22, no. 9 (2013): 1921-1935.

[383] H. J. Hijma, P. S. Siebenga, M. L. de Kam, and G. J. Groeneveld, “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults,” Pain Medicine (Malden, Mass.) 22, no. 8 (2021): 1814-1826.

[384] A.-P. Koivisto, M. G. Belvisi, R. Gaudet, and A. Szallasi, “Advances in TRP Channel Drug Discovery: From Target Validation to Clinical Studies,” Nature Reviews Drug Discovery 21, no. 1 (2021): 41-59.

[385] D. Bates, B. C. Schultheis, M. C. Hanes, et al., “A Comprehensive Algorithm for Management of Neuropathic Pain,” Pain Medicine (Malden, Mass.) 20, no. Suppl 1 (2019): S2-S12.

[386] H. Gaskell, S. Derry, C. Stannard, and R. A. Moore, “Oxycodone for Neuropathic Pain in Adults,” Cochrane Database of Systematic Reviews (Online) 7, no. 7 (2016): Cd010692.

[387] J. Faria, J. Barbosa, R. Moreira, O. Queirós, F. Carvalho, and R. J. Dinis-Oliveira, “Comparative Pharmacology and Toxicology of Tramadol and Tapentadol,” European Journal of Pain (London, England) 22, no. 5 (2018): 827-844.

[388] D. Cosio and T. Schafer, “Implementing an Acceptance and Commitment Therapy Group Protocol With Veterans Using VA's Stepped Care Model of Pain Management,” Journal of Behavioral Medicine 38, no. 6 (2015): 984-997.

[389] D. J. Clauw, “Fibromyalgia: A Clinical Review,” Jama 311, no. 15 (2014): 1547-1555.

[390] H. Birkinshaw, C. M. Friedrich, P. Cole, et al., “Antidepressants for Pain Management in Adults With Chronic Pain: A Network Meta-analysis,” Cochrane Database of Systematic Reviews (Online) 5, no. 5 (2023): CD014682.

[391] K. Tran and D. MacDougall, “CADTH Health Technology Review,” In: Ketamine for Chronic Non-Cancer Pain: A 2023 Update: CADTH Health Technology Review (Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2023).

[392] G. Marciano, C. Vocca, M. Evangelista, et al., “The Pharmacological Treatment of Chronic Pain: From Guidelines to Daily Clinical Practice,” Pharmaceutics 15, no. 4 (2023): 1165.

[393] T. Toubia and T. Khalife, “The Endogenous Opioid System: Role and Dysfunction Caused by Opioid Therapy,” Clinical Obstetrics and Gynecology 62, no. 1 (2019): 3-10.

[394] I. M. Rosen, R. N. Aurora, D. B. Kirsch, et al., “Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement,” Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine 15, no. 11 (2019): 1671-1673.

[395] L. Maia, I. Chaves, H. Medeiros, G. F. Silva, and W. A. da Silva, “Impact of Opioids on Hospital Stay and Mortality in Patients Undergoing Abdominal Surgeries,” Anesthesiology and Perioperative Science 2, no. 4 (2024).

[396] O. Yoo, E. K. Y. Tang, S. Salman, et al., “A Randomised Controlled Trial of a Novel tramadol Chewable Tablet: Pharmacokinetics and Tolerability in Children,” Anaesthesia 77, no. 4 (2022): 438-448.

[397] R. Freynhagen, C. Elling, T. Radic, et al., “Safety of tapentadol Compared With Other Opioids in Chronic Pain Treatment: Network Meta-analysis of Randomized Controlled and Withdrawal Trials,” Current Medical Research and Opinion 37, no. 1 (2021): 89-100.

[398] R. Guo, L. H. Chen, C. Xing, and T. Liu, “Pain Regulation by Gut Microbiota: Molecular Mechanisms and Therapeutic Potential,” British Journal of Anaesthesia 123, no. 5 (2019): 637-654.

[399] L. H. Morais, HLt Schreiber, and S. K. Mazmanian, “The Gut Microbiota-brain Axis in Behaviour and Brain Disorders,” Nature Reviews Microbiology 19, no. 4 (2021): 241-255.

[400] F. A. Amaral, D. Sachs, V. V. Costa, et al., “Commensal Microbiota Is Fundamental for the Development of Inflammatory Pain,” PNAS 105, no. 6 (2008): 2193-2197.

[401] A. T. Vieira, L. Macia, I. Galvão, et al., “A Role for Gut Microbiota and the Metabolite-Sensing Receptor GPR43 in a Murine Model of Gout,” Arthritis Rheumatol 67, no. 6 (2015): 1646-1656.

[402] E. Vaghef-Mehrabany, B. Alipour, A. Homayouni-Rad, S. K. Sharif, M. Asghari-Jafarabadi, and S. Zavvari, “Probiotic Supplementation Improves Inflammatory Status in Patients With Rheumatoid Arthritis,” Nutrition (Burbank, Los Angeles County, Calif) 30, no. 4 (2014): 430-435.

[403] D. R. Mandel, K. Eichas, and J. Holmes, “Bacillus Coagulans: A Viable Adjunct Therapy for Relieving Symptoms of Rheumatoid Arthritis According to a Randomized, Controlled Trial,” BMC Complementary and Alternative Medicine [Electronic Resource] 10 (2010): 1.

[404] P. Chen, C. Wang, Y. N. Ren, Z. J. Ye, C. Jiang, and Z. B. Wu, “Alterations in the Gut Microbiota and Metabolite Profiles in the Context of Neuropathic Pain,” Mol Brain 14, no. 1 (2021): 50.

[405] W. Ding, Z. You, Q. Chen, et al., “Gut Microbiota Influences Neuropathic Pain through Modulating Proinflammatory and Anti-inflammatory T Cells,” Anesthesia and Analgesia 132, no. 4 (2021): 1146-1155.

[406] P. Ma, R. Mo, H. Liao, et al., “Gut Microbiota Depletion by Antibiotics Ameliorates Somatic Neuropathic Pain Induced by Nerve Injury, Chemotherapy, and Diabetes in Mice,” Journal of Neuroinflammation 19, no. 1 (2022): 169.

[407] H. R. Wardill, R. J. Gibson, Y. Z. Van Sebille, et al., “Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms,” Molecular Cancer Therapeutics 15, no. 6 (2016): 1376-1386.

[408] F. Zhou, X. Wang, B. Han, et al., “Short-chain Fatty Acids Contribute to Neuropathic Pain via Regulating Microglia Activation and Polarization,” Mol Pain 17 (2021): 1744806921996520.

[409] Z. Mamieva, E. Poluektova, V. Svistushkin, et al., “Antibiotics, Gut Microbiota, and Irritable Bowel Syndrome: What Are the Relations?,” World Journal of Gastroenterology 28, no. 12 (2022): 1204-1219.

[410] L. Kang, W. Tang, Y. Zhang, et al., “The Gut Microbiome Modulates Nitroglycerin-induced Migraine-related Hyperalgesia in Mice,” Cephalalgia : an International Journal of Headache 42, no. 6 (2022): 490-499.

[411] M. Pimentel, W. Morales, K. Chua, et al., “Effects of rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects,” Digestive Diseases and Sciences 56, no. 7 (2011): 2067-2072.

[412] T. Ringel-Kulka, J. R. Goldsmith, I. M. Carroll, et al., “Lactobacillus Acidophilus NCFM Affects Colonic Mucosal Opioid Receptor Expression in Patients With Functional Abdominal Pain—a Randomised Clinical Study,” Alimentary Pharmacology & Therapeutics 40, no. 2 (2014): 200-207.

[413] A. Horvath, P. Dziechciarz, and H. Szajewska, “Meta-analysis: Lactobacillus Rhamnosus GG for Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood,” Alimentary Pharmacology & Therapeutics 33, no. 12 (2011): 1302-1310.

[414] J. Sensenig, M. Johnson, and T. Staverosky, “Treatment of Migraine With Targeted Nutrition Focused on Improved Assimilation and Elimination,” Alternative Medicine Review : a Journal of Clinical Therapeutic 6, no. 5 (2001): 488-494.

[415] S.-Y. Zhou, M. Gillilland, X. Wu, et al., “FODMAP Diet Modulates Visceral Nociception by Lipopolysaccharide-mediated Intestinal Inflammation and Barrier Dysfunction,” Journal of Clinical Investigation 128, no. 1 (2017): 267-280.

[416] P. Singh, G. Grabauskas, S. Y. Zhou, J. Gao, Y. Zhang, and C. Owyang, “High FODMAP Diet Causes Barrier Loss via Lipopolysaccharide-mediated Mast Cell Activation,” JCI Insight 6, no. 22 (2021): e146529.

[417] T. Thurm, J. N. Ablin, D. Buskila, and N. Maharshak, “Fecal Microbiota Transplantation for Fibromyalgia: A Case Report and Review of the Literature,” Open Journal of Gastroenterology 7 (2017): 131-139.

[418] L. Jia, “Nanoparticle Formulation Increases Oral Bioavailability of Poorly Soluble Drugs: Approaches Experimental Evidences and Theory,” Current Nanoscience 1, no. 3 (2005): 237-243.

[419] D. Bhansali, S. L. Teng, C. S. Lee, B. L. Schmidt, N. W. Bunnett, and K. W. Leong, “Nanotechnology for Pain Management: Current and Future Therapeutic Interventions,” Nano Today (2021): 39.

[420] C. Zhao, A. Liu, C. M. Santamaria, et al., “Polymer-tetrodotoxin Conjugates to Induce Prolonged Duration Local Anesthesia With Minimal Toxicity,” Nature Communications 10, no. 1 (2019): 2566.

[421] S. Kataria, U. Patel, K. Yabut, et al., “Recent Advances in Management of Neuropathic, Nociceptive, and Chronic Pain: A Narrative Review With Focus on Nanomedicine, Gene Therapy, Stem Cell Therapy, and Newer Therapeutic Options,” Current Pain and Headache Reports 28, no. 5 (2024): 321-333.

[422] A. Le Franc, A. Da Silva, and S. Lepetre-Mouelhi, “Nanomedicine and Voltage-gated Sodium Channel Blockers in Pain Management: A Game Changer or a Lost Cause?,” Drug Deliv Transl Res 14, no. 8 (2024): 2112-2145.

[423] C. Zhan, W. Wang, J. B. McAlvin, et al., “Phototriggered Local Anesthesia,” Nano Letters 16, no. 1 (2016): 177-181.

[424] S. A. Shankarappa, J. H. Tsui, K. N. Kim, et al., “Prolonged Nerve Blockade Delays the Onset of Neuropathic Pain,” PNAS 109, no. 43 (2012): 17555-17560.

[425] Y. Zhang, X. Xu, Y. Tong, et al., “Therapeutic Effects of Peripherally Administrated Neural Crest Stem Cells on Pain and Spinal Cord Changes After Sciatic Nerve Transection,” Stem Cell Research & Therapy 12, no. 1 (2021): 180.

[426] F. Li, L. Liu, K. Cheng, Z. Chen, and J. Cheng, “The Use of Stem Cell Therapy to Reverse Opioid Tolerance,” Clinical Pharmacology and Therapeutics 103, no. 6 (2018): 971-974.

[427] M. Li, J. Li, H. Chen, and M. Zhu, “VEGF-Expressing Mesenchymal Stem Cell Therapy for Safe and Effective Treatment of Pain in Parkinson's Disease,” Cell Transplantation 32 (2023): 9636897221149130.

[428] T. E. Ichim, F. Solano, F. Lara, et al., “Feasibility of Combination Allogeneic Stem Cell Therapy for Spinal Cord Injury: A Case Report,” International Archives of Medicine 3 (2010): 30.

[429] E. R. Vickers, E. Karsten, J. Flood, and R. Lilischkis, “A Preliminary Report on Stem Cell Therapy for Neuropathic Pain in Humans,” J Pain Res 7 (2014): 255-263.

[430] L. Orozco, R. Soler, C. Morera, M. Alberca, A. Sanchez, and J. Garcia-Sancho, “Intervertebral Disc Repair by Autologous Mesenchymal Bone Marrow Cells: A Pilot Study,” Transplantation 92, no. 7 (2011): 822-828.

[431] K. Elverum and M. Whitman, “Delivering Cellular and Gene Therapies to Patients: Solutions for Realizing the Potential of the next Generation of Medicine,” Gene Therapy 27, no. 12 (2020): 537-544.

[432] S. V. Ovsepian and S. G. Waxman, “Gene Therapy for Chronic Pain: Emerging Opportunities in Target-rich Peripheral Nociceptors,” Nature Reviews Neuroscience 24, no. 4 (2023): 252-265.

[433] A. M. Moreno, F. Aleman, G. F. Catroli, et al., “Long-lasting Analgesia via Targeted in Situ Repression of Na(V)1.7 in Mice,” Science Translational Medicine 13, no. 584 (2021): eaay9056.

[434] S. He, V. O. Zambelli, P. Sinharoy, et al., “A human TRPV1 Genetic Variant Within the Channel Gating Domain Regulates Pain Sensitivity in Rodents,” Journal of Clinical Investigation 133, no. 3 (2023): e163735.

[435] C. R. Fertleman, M. D. Baker, K. A. Parker, et al., “SCN9A mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes,” Neuron 52, no. 5 (2006): 767-774.

[436] H. Yu, S. M. Shin, H. Xiang, et al., “AAV-encoded Ca(V)2.2 Peptide Aptamer CBD3A6K for Primary Sensory Neuron-targeted Treatment of Established Neuropathic Pain,” Gene Therapy 26, no. 7-8 (2019): 308-323.

[437] B. Nho, K. R. Ko, S. Kim, and J. Lee, “Intramuscular Injection of a Plasmid DNA Vector Expressing Hepatocyte Growth Factor (HGF) Ameliorated Pain Symptoms by Controlling the Expression of Pro-inflammatory Cytokines in the Dorsal Root Ganglion,” Biochemical and Biophysical Research Communications 607 (2022): 60-66.

[438] C. Hu, Y. Lu, X. Cheng, Y. Cui, Z. Wu, and Q. Zhang, “Gene Therapy for Neuropathic Pain Induced by Spared Nerve Injury With Naked Plasmid Encoding Hepatocyte Growth Factor,” The Journal of Gene Medicine 19, no. 12 (2017): 2994.

[439] J. A. Kessler, A. Shaibani, C. N. Sang, et al., “Gene Therapy for Diabetic Peripheral Neuropathy: A Randomized, Placebo-controlled Phase III Study of VM202, a Plasmid DNA Encoding human Hepatocyte Growth Factor,” Clinical and Translational Science 14, no. 3 (2021): 1176-1184.

[440] M. A. Clements, A. J. Kwilasz, S. T. Litwiler, et al., “Intrathecal Non-viral Interleukin-10 Gene Therapy Ameliorates Neuropathic Pain as Measured by both Classical Static Allodynia and a Novel Supra-spinally Mediated Pain Assay, the Two-Arm Rodent Somatosensory (TARS) Task,” Brain, Behavior, and Immunity 111 (2023): 177-185.

[441] L. R. Watkins, R. A. Chavez, R. Landry, et al., “Targeted Interleukin-10 Plasmid DNA Therapy in the Treatment of Osteoarthritis: Toxicology and Pain Efficacy Assessments,” Brain, Behavior, and Immunity 90 (2020): 155-166.

[442] J. Nijs, A. Lahousse, E. Kapreli, et al., “Nociplastic Pain Criteria or Recognition of Central Sensitization? Pain Phenotyping in the Past, Present and Future,” Journal of Clinical Medicine 10, no. 15 (2021): 3203.

[443] Y. I. Asiri and M. Zaheen Hassan, “An Overview of Ion Channels Therapeutics in the Treatment of Pain,” Arabian Journal of Chemistry 16, no. 10 (2023).

[444] A. Uniyal, V. Tiwari, T. Tsukamoto, X. Dong, Y. Guan, and S. N. Raja, “Targeting Sensory Neuron GPCRs for Peripheral Neuropathic Pain,” Trends in Pharmacological Sciences 44, no. 12 (2023): 1009-1027.

[445] F. W. Pun, I. V. Ozerov, and A. Zhavoronkov, “AI-powered Therapeutic Target Discovery,” Trends in Pharmacological Sciences 44, no. 9 (2023): 561-572.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.